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ABSTRACT 
 Sexual functioning is associated with symptoms of depression, which occurs at rates much 
higher than that in the general population. Treatment of depression and remission of depressive 
symptoms can improve sexual functioning; however, antidepressants and other medications may 
cause or worsen sexual functioning. Assessment of sexual dysfunction in the past has 
predominantly relied on the patient spontaneously reporting problems with sexual functioning to 
their physician or other medical professional. Due to the sensitive nature of the topic, patient 
reporting is typically low and does not reflect the actual prevalence of sexual dysfunction. This 
research assessed the rate and level of antidepressant treatment-associated sexual dysfunction as 
assessed by validated questionnaire in published and unpublished data. 
 Studies eligible for inclusion were randomized, double-blind, placebo-controlled trials 
evaluating the antidepressant effect in patients with acute major depression. Studies must have 
included approved antidepressants evaluating doses in the therapeutic range and include a 
validated questionnaire to assess sexual functioning, i.e., the ASEX or CSFQ. The studies must 
have included sufficient data to calculated mean standardized effect sizes and/or odds ratios for 
developing sexual dysfunction. 
 The initial search yielded 320 records. After review for eligibility and completeness, the 
searched yielded 17 studies for inclusion in this meta-analysis. Sexual dysfunction odds ratios 
and standardized mean effect sizes for antidepressant versus placebo were calculated. Where 
available, odds ratios and mean effect sizes were also calculated by sex. 
 ix 
 The odds of developing sexual dysfunction with paroxetine, escitalopram and duloxetine 
were significantly worse than placebo. Evaluation by gender indicated that for women the odds 
of developing sexual dysfunction with desvenlafaxine was also significantly worse than placebo. 
Standardized mean effect sizes indicated significantly worse sexual functioning versus placebo 
for escitalopram and paroxetine with both sexes combined. Significant differences were also 
found for men taking vilazodone. Conclusions of this meta-analysis are limited by the number of 
studies included. For some antidepressants there was only one study that qualified. Not all 
studies provided data by sex. Gender effects are apparent with some antidepressants, so this data 
is of particular interest when evaluating the risk of developing sexual dysfunction.  
 1 
 
 
CHAPTER ONE 
OVERVIEW 
Sexual dysfunction is a disruption in the normal sexual response cycle and typically affects the 
desire, arousal, and/or orgasm phase(s). Sexual dysfunction occurs in approximately one-third of 
the general population; however, the prevalence increases with certain comorbid conditions. 
Several factors that contribute to the level of dysfunction are: medical illnesses, such as, obesity, 
diabetes, cardiovascular disease, sexually transmitted diseases, and urinary tract infection; 
alcohol consumption; substance abuse; social status; sexual trauma; medications; emotional 
issues; and psychiatric illness. The particular focus of this work addresses sexual dysfunctioning 
associated with depression and in response to antidepressant drug treatments, which occur at 
rates much higher than that in the general population.  
 Depression is associated with many symptoms that can have a negative effect on intimacy 
and sexual relationships; i.e., persistent sadness, loss of interest in activities once pleasurable, 
decreased energy, feelings of worthlessness, and irritability and social withdrawal. Treatment of 
depression and remission of depressive symptoms can improve sexual functioning; however, 
antidepressants and other medications may cause or worsen sexual functioning, which is referred 
to as treatment-induced or treatment-emergent sexual dysfunction. In the literature, there is a 
wide range reported in the level of sexual dysfunction associated with various antidepressants. 
Medications with a predominantly serotonergic mechanism of action (MOA), such as the 
Selective Serotonin Reuptake Inhibitors (SSRIs), are associated with higher rates of sexual 
dysfunction compared to drugs that primarily exhibit a non-serotonergic MOA. For example, 
2 
 
medications, such as buproprion, which primarily exhibit dopaminergic and noradrenergic 
effects, are associated with little or no sexual dysfunction. Antidepressants not only differ in the 
level of impact on sexual functioning, but there are also differences in other tolerability 
parameters and in efficacy, which vary across individuals, thus making selection of medication 
therapy multifaceted and to a great extent individualized.  
 Treatment-associated side-effects often affect medication compliance and may lead to 
discontinuation of treatment. Lack of medication compliance is a significant issue as this can 
interfere with the treatment of depression, often resulting in an incomplete response or lack of 
remission of depressive symptoms. Depression is associated with significant reductions in 
quality of life, impaired productivity, and reduced overall health, and according to the Centers 
for Disease Control and Prevention is the 10th leading cause of death in the United States. In 
addition, sexual dysfunction is a commonly reported side-effect that often results in medication 
discontinuation. 
 Assessment of sexual dysfunction in the past has predominantly relied on the patient 
spontaneously reporting problems with sexual functioning to their physician or other medical 
professional. Due to the sensitive nature of the topic, patient reporting is typically low and does 
not reflect the actual prevalence of sexual dysfunction. Several prospective questionnaires have 
been developed in order to more accurately assess the true levels of dysfunction associated with 
medication treatment or illnesses. Most of the antidepressant-associated sexual dysfunction data 
reported in the literature are from individual studies and include active treatment versus placebo, 
treatment versus active comparator, or both. Comparing across studies to judge the comparative 
level of sexual dysfunction is difficult due to natural variation across studies, and the use of 
different assessment tools. A few meta-analyses and other systematic reviews have been 
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conducted to address the issue of comparisons across antidepressants; however, the body of 
research has grown, the methods for assessing sexual dysfunction have become more systematic, 
and new, differentiated antidepressants have entered the market. Therefore, a current meta-
analysis would provide useful information in the understanding of antidepressant associated 
sexual dysfunction.  
 The purpose of this research is to assess the rate and level of antidepressant treatment-
associated sexual dysfunction as assessed by validated questionnaire in published and 
unpublished data. The inclusion of unpublished data from Clinicaltrials.gov, pharmaceutical 
websites, The Food and Drug Administration (FDA) summary basis of approval documents and 
other sources will add further insight into the effects of antidepressants on sexual functioning. 
The objectives of this analysis are to assess the rates of sexual dysfunction and to assess the level 
of sexual dysfunction associated with commonly prescribed antidepressants and placebo. 
 The outcome of this research adds to the body of knowledge available on treatment-
associated sexual dysfunction. In the typical clinical setting, it is relatively uncommon for 
clinicians to proactively question depressed patients regarding their sexual functioning. It is 
equally unlikely that patients will bring up this topic with their healthcare provider. Usually, the 
most urgent treatment goals are addressed initially (depressed mood, feelings of hopelessness, 
worthlessness and any potential suicidal ideation of behaviors) and residual symptoms are often 
considered as something to tolerate or perhaps deal with later. Unfortunately, the residual 
symptoms of sexual dysfunction are often left unaddressed and can eventually lead to poor 
overall treatment outcomes, lack of treatment compliance, remission and recurrence. Both 
patients as well as healthcare providers are often hesitant to switch medications if the majority of 
the depressed symptoms appear to be controlled. In part, the reluctance to address sexual 
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dysfunction is due to the lack of effective and tolerable alternatives for an individual patient, as 
well as lack of knowledge of the relative sexual dysfunction associated with available 
antidepressants.   
 This research will provide a means for healthcare providers to reference the rates of sexual 
dysfunction, including the recently approved antidepressants, among the second-generation 
antidepressants. Having these data available as a meta-analysis provides a systematic, 
standardized and comparative assessment, which is difficult to perform when reviewing 
individual studies.
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CHAPTER TWO 
INTRODUCTION 
The normal human sexual response cycle is generally described as having four phases: (1) Desire 
or libido, characterized by an interest in sexual activity, (2) Excitement or arousal, the subjective 
sense of sexual pleasure accompanied by physiological changes (including penile erection in 
men, and vaginal lubrication and clitoral engorgement in women), (3) Orgasm, the peaking of 
sexual pleasure and release of tension, and (4) Resolution, the sense of muscular relaxation and 
general well-being (Masters & Johnson, 1966; Kaplan, 1979; Levin, 2008). Sexual dysfunction is 
characterized by a disruption in the normal sexual response cycle and typically affects the desire, 
arousal, and/or orgasm phase(s) (DSM-IV, 1994). Sexual dysfunction is prevalent and occurs in 
approximately one-third of the general population. Some estimates report that as many as 43% of 
women and 31% of men experience some degree of sexual dysfunction (Laumann et al., 1999). 
Most studies have shown that a greater percentage of women than men report issues with sexual 
functioning (Montgomery et al., 2002). In both sexes, the most common complaint is decreased 
libido. In men, erectile dysfunction and premature ejaculation are common complaints; in 
women, failure to achieve orgasm is often reported. There are several factors that contribute to 
problems in normal sexual functioning, including medical illnesses (e.g., obesity, diabetes, 
cardiovascular disease, sexually transmitted diseases, urinary tract infection, etc.), alcohol 
consumption, substance abuse, social status, sexual trauma, medications, emotional issues and 
psychiatric illness (e.g., depression or anxiety) (Laumann et al., 1999; Baldwin, 2001; Zajecka, 
2001).  
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 Sexual dysfunction is a frequently reported symptom of depression and comparative studies 
consistently report higher rates of sexual dysfunction in depressed patients compared to the 
general population. Some studies have reported loss of sexual interest in approximately 70% of 
depressed patients (Casper et al., 1985). A more recent prospective study (Zurich Cohort Study) 
of 591 males and females from the general population of Zurich reported the prevalence of 
sexual dysfunction in depressed patients as 50% versus 24% in non-depressed patients (Angst, 
1998).  Prior studies had reported on the association of sexual dysfunction and depression, but 
had not systematically studied this association in untreated patients. Kennedy et al. (1999) 
conducted a study of 134 men and women with depression who were willing to complete a 
sexual functioning questionnaire before initiating antidepressant treatment. The results of this 
study also indicated high levels of sexual dysfunction in patients who were currently 
experiencing a major depressive episode. Approximately 50% of the women and 25% of the men 
reported no sexual activity during the preceding month and 50% of women and 42% of men 
reported a decrease in sexual desire. The most commonly reported issues with arousal in sexually 
active patients were inability to sustain erection in men (46%) and less sexual arousal in women 
(50%). 
 A 2013 review and meta-analysis conducted to assess the bidirectional relationship of 
depression and sexual dysfunction, evaluated six studies on the risk of depression in patients 
with sexual dysfunction, and six studies on the risk of sexual dysfunction in patients with 
depression (Atlantis et al., 2012). The results of this review demonstrated that depressed patients 
had a 50% to 70% increased risk of developing sexual dysfunction and those with sexual 
dysfunction had a 130% to 210% increased risk of developing depression, reinforcing other data 
demonstrating the inter-relatedness of sexual dysfunction and depression. 
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Pathophysiology of Depression and Sexual Functioning 
Depression is characterized by persistent sadness, loss of interest in activities once pleasurable 
(including sex), decreased energy, feelings of worthlessness, irritability and social withdrawal; 
symptoms which may adversely affect intimate relationships and create difficulties in sexual 
relationships (Baldwin, 2001). The three main monoamine systems involved in the 
pathophysiology of depression are serotonin (5-hydroxytryptamine, 5-HT), noradrenaline (NE), 
and dopamine (DA). Postmortem, cerebrospinal fluid (CSF) and positron emission tomography 
(PET) imaging studies in depressed unmedicated individuals have demonstrated decreased 5-HT, 
NE and DA availability in the central nervous system (Nemeroff, 2008).  
 Most antidepressants function by increasing availability of serotonin in the brain; many also 
increase the availability of noradrenaline and/or dopamine. Newer antidepressants (often referred 
to as second generation), such as the selective serotonin reuptake inhibitors (SSRIs), have many 
improvements over older antidepressants (e.g., tricyclics), particularly in safety; however, 
response to SSRIs has been incomplete for many patients. This has led to further development of 
antidepressants targeting the NE and/or DA systems (e.g., serotonin norepinephrine reuptake 
inhibitors [SNRIs] or ‘atypical’ antidepressants such as buproprion, nefazodone, mirtazapine,  
vilazodone, and vortioxetine).   
 Sexual function is regulated by complex interactions between the endocrine and nervous 
systems. Among the hormones that may impact sexual function, testosterone, estrogen, and 
oxytocin appear to have greater roles in facilitation of the desire, arousal and/or orgasm phases of 
sexual response (Meston & Frohlich, 2000; Anil Kumar et al., 2009; Clayton & Montejo, 2006). 
Neurotransmitters also appear to have a significant impact on sexual functioning. Data indicate 
that there is a positive association between DA levels and desire and motivation for sexual 
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activity; and in men, DA may be linked to penile erection. In men, NE levels positively correlate 
with arousal and erection during masturbation and sexual activity. Some data have shown that 
levels of NE increased up to 12-fold at orgasm and returned to baseline within 2 minutes of 
orgasm. In women, blood plasma levels of NE increased during masturbation, peaked at orgasm 
and declined after orgasm (Exton et al., 1999). The basis for targeting the DA system to improve 
efficacy over SSRIs lies in the fact that the inability to experience pleasure is a significant 
symptom of depression; and pleasure, regardless of the activity (including sexual behavior), is 
primarily mediated by DA neurons and related neuronal circuits (Nemeroff, 2008). 
Antidepressant Treatment-Associated Sexual Dysfunction 
Treatment of depression and remission of depressive symptoms can improve sexual functioning; 
however, antidepressants and other medications may cause or worsen sexual functioning, which 
is referred to as treatment-induced or treatment-emergent sexual dysfunction. Because sexual 
dysfunction is associated with comorbid conditions, including depression as well as medication 
treatment, and in many cases the cause-effect relationship cannot be determined, the term 
treatment-associated sexual dysfunction (TASD) is often used to describe this phenomenon. In 
the Zurich Cohort Study (Angst, 1998), a comparison was performed between depressed patients 
who received only psychotherapy or treatment with medication (50% received benzodiazepines 
and 50% received antidepressants) versus those who received no treatment. Approximately 62% 
of depressed patients who received medication experienced sexual problems as compared to 45% 
of untreated depressed patients. Interestingly, the group of depressed patients who received 
psychotherapy alone experienced an equally high rate (63%) of sexual dysfunction.  
 One meta-analysis of several antidepressants reported between 25% and 80% of people 
taking antidepressants experience sexual dysfunction, depending on the medication they were 
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taking (Serretti & Chiesa, 2009). In this analysis, the rate of sexual dysfunction in patients on 
placebo was 14%, which is lower than the rate of sexual dysfunction in depressed patients 
reported elsewhere in the literature indicating that the assessment of rates of sexual dysfunction 
varies widely across studies. 
 Problems with sexual functioning can begin as early as 7 days after treatment with 
medication, depending on the antidepressant, and improvement can also occur shortly after 
discontinuation of treatment (Anita Clayton MD, personal communication). Ideally, this would 
make the assessment of causality of sexual dysfunction and antidepressant treatment more 
straight-forward given confounding factors are limited. 
 The understanding of sexual functioning has increased since the introduction of newer 
antidepressants. Older generation antidepressants were associated with sexual dysfunction, but 
were not selective in their effects on neurotransmitters (e.g., MAOIs). As SSRIs are selective in 
that they specifically increase serotonin activity, the relationship between serotonin and sexual 
response has been further clarified. Medications with a predominantly serotonergic mechanism 
of action, e.g., the SSRI paroxetine, may be associated with the highest incidence of TASD 
(~70%) compared to drugs that primarily exhibit a non-serotonergic MOA (Kennedy & Rizvi, 
2009). Specifically, increased serotonin activity is associated with decreased libido and impaired 
ejaculation (Meston & Frohlich, 2000). Often the symptoms of sexual dysfunction are mitigated 
by a reduction in dose of the antidepressant. Furthermore, some SSRIs have been shown to be 
useful in the treatment of premature ejaculation by increasing the latency to orgasm (Waldinger 
et al., 1998).  
 As discussed above, the level of DA and NE affects the desire, arousal and orgasm phases of 
the sexual response cycle. Antidepressants that primarily exhibit a non-serotonergic MOA be 
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associated with fewer sexual side-effects than SSRIs. Some studies show that antidepressants 
that have noradrenergic and well as serotonergic effects (SNRIs such as duloxetine, mirtazapine, 
and venlafaxine) are associated with less sexual dysfunction, suggesting that increased 
noradrenaline may mitigate the deleterious effect of serotonin on sexual dysfunction (Kennedy & 
Rizvi, 2009). In one study, TASD was significantly lower with the SNRI duloxetine as compared 
to the SSRI paroxetine (46% versus 61%); however, both were significantly worse than placebo 
(Delgado et al., 2005). Medications that exhibit dopaminergic as well as noradrenergic actions 
(e.g., buproprion) have been associated with little or no sexual side-effects, and are often used as 
add-on therapies to counteract antidepressant-induced sexual dysfunction (Kennedy & Rizvi, 
2009). In another study of TASD in patients taking one of several SSRIs or buproprion, rates of 
sexual dysfunction ranged from 30% for citalopram and venlafaxine to 7% for buproprion 
(Clayton et al., 2002).  
 A recently updated review from The Cochrane Collaboration (Taylor et al., 2013) evaluated 
the effectiveness of various management strategies for sexual dysfunction associated with 
antidepressants. Twenty-three studies that met the selection criteria were included in the meta-
analysis. The strategies evaluated in these studies included the addition of further medication (22 
studies) and change in antidepressant medication (one study). Based on this review, most 
augmentation studies failed to show significant improvements in sexual dysfunction compared to 
placebo; however, the addition of buproprion improved sexual functioning in men and women, 
and the addition of sildenafil (Viagra) indicated greater improvement in erectile function over 
placebo in men. 
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Impact of TASD on the Treatment of Depression 
Treatment-associated side-effects often affect medication compliance and may lead to 
discontinuation of treatment. One study surveyed 350 depressed patients regarding compliance 
with antidepressant treatment and reasons for noncompliance and/or discontinuation (Ashton et 
al., 2005). Of the 350 patients surveyed, 60% had completely discontinued treatment with the 
most common reasons being lack of efficacy (44%), “didn’t like the way the medicine made me 
feel” (37%), “lost interest in sex” (23%), “tiredness” (18%) and “weight gain” (16%). Of those 
currently prescribed an antidepressant (97%), 22% indicated they were noncompliant, with 
“couldn’t have an orgasm” (20%) and “lost interest in sex” (20%) reported as reasons for 
noncompliance by those patients. In addition, “lost interest in sex” was reported by 47% of all 
patients prescribed an antidepressant with “unable to have erection” and “difficulty reaching 
orgasm” considered to be “extremely difficult to live with” by 25% and 24% of the patients, 
respectively. Although there are not many studies assessing patient self-reported reasons for 
noncompliance, sexual dysfunction is a commonly reported side-effect associated with treatment 
and does lead to medication discontinuation and often switching antidepressants to find one that 
produces less sexual dysfunction. 
 Lack of medication compliance is a significant issue as this can interfere with the treatment 
of depression, leading to lack of, or incomplete response or remission of depressive symptoms.  
Depression is associated with significant reductions in quality of life, impaired productivity, 
reduced overall health, and substantial economic burden (World Health Organization, 2012; 
Bech et al., 2006). Depression is also associated with an increased risk of suicide (Reeves & 
Ladner, 2010; Stone et al., 2009; Barbui et al., 2009). According to The World Health 
Organization (WHO), major depression is a leading cause of disease burden in North America 
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and the fourth leading cause worldwide as of year 2000. By year 2020, WHO estimates that 
depression will be the second leading cause of global burden of disease. In the United States, 
major depressive disorder (MDD) affects 5-7% of people each year, and 13-16% of individuals 
during their lifetime (Hasin et al., 2005; Kessler et al., 2003; Kessler, Berglund et al., 2005; 
Kessler, Chui et al., 2005); therefore, lack of treatment compliance due to side-effects, in 
general, and TASD, specifically, can have significant impact on those suffering from depression.   
Assessment of Sexual Functioning 
Initially, assessment of sexual dysfunction relied on the patient spontaneously reporting sexual 
functioning-related adverse events. Patient reporting is typically low and does not reflect the 
actual prevalence of sexual dysfunction. In one study of 344 patients using SSRIs, spontaneously 
reported sexual dysfunction was 14.2% compared to 58.1% when reported via questionnaire 
(Montejo-Gonzalez et al., 1997). As a result of the propensity to under-report sexual side-effects, 
prospective questionnaires were designed in order to obtain a more accurate assessment of sexual 
dysfunction. Several questionnaires have been developed to assess sexual dysfunction in 
patients; some are administered via interview (e.g., Psychotropic-Related Sexual Dysfunction 
Questionnaire [PRSexDQ]), self-reported or by interview (e.g., Arizona Sexual Experiences 
Scale [ASEX], Changes in Sexual Functioning Questionnaire [CSFQ], Rush Sexual Inventory 
Scale, and Sex Effects Scale), and are usually available in male and female versions. Most record 
sexual functioning using categories on a Likert scale, but some assess sexual functioning using 
anchors on a visual analog scale (VAS). Criteria are often identified that categorize the patient as 
having normal or abnormal sexual dysfunction and many have subscales that assess the three 
main phases of the sexual response cycle: desire, arousal, and orgasm.   
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 In one study of 1022 patients that utilized a prospective questionnaire (PRSexDQ) conducted 
by the Spanish Working Group of Psychotropic-related Sexual Dysfunction, sexual dysfunction 
associated with antidepressants as a whole was 62.4% for men and 56.9% for women, although 
women reported greater severity of sexual dysfunction (Montejo, et al., 2001). A meta-analysis 
of studies exploring antidepressant-related sexual dysfunction was conducted by Serretti and 
Chiesa (2009). This analysis examined the overall rate of treatment-emergent sexual dysfunction 
as well as the rates of dysfunction in the sexual response phases of desire, arousal, and orgasm. 
The authors targeted studies examining antidepressant-related sexual dysfunction in patients 
without prior sexual dysfunction, and the method of acquiring data was through direct inquiry or 
patient completed questionnaires. In addition to direct inquiry, various scales were included, but 
the most common were the ASEX and CSFQ. The literature review for this analysis was 
performed on published studies through July 2008 using MEDLINE. While this study included 
useful data on many of the commonly prescribed antidepressants, as the authors note the research 
is subject to publication bias. In addition, the field of study in TASD has increased over the last 
several years and more articles have been published on newer antidepressants.  
 A more recent meta-analysis by Reichenpfader et al. (2014) evaluated the comparative harms 
of second-generation antidepressants in depressed patients utilizing network analysis. The 
authors concluded that the comparative risk of sexual dysfunction associated with specific 
antidepressants could not be precisely determined due in part to the variation of sexual 
dysfunction adverse events reported across studies for a given antidepressant. The variation seen 
across studies could have been impacted by the inclusion of data gathered by various methods, 
including spontaneously reported adverse events. Therefore, a review that includes only sexual 
dysfunction data from prospective questionnaires may reduce the variation in reporting and 
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provide a greater distinction in the relative incidence of sexual dysfunction associated with 
antidepressant treatment.  
 The purpose of this research is to assess the rate and level of treatment-associated sexual 
dysfunction as assessed by questionnaire in published and unpublished data (i.e., 
clinicaltrials.gov, pharmaceutical company websites and The Food and Drug Administration 
(FDA) summary basis of approval documents were reviewed). Data from these sources are 
publicly available, but many of the studies are not published in journals. Including these data will 
add further insight into the effects of antidepressants on sexual functioning. 
Objectives 
The objectives of this research are to assess the rates, and the level of sexual dysfunction 
associated with commonly prescribed antidepressants versus placebo.
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CHAPTER THREE 
METHODS 
This research is a systematic review and meta-analysis of the rates of treatment-associated sexual 
dysfunction in depressed patients taking commonly prescribed antidepressants approved in the 
United States. This analysis evaluated the level of sexual dysfunction in the intent-to-treat 
population (i.e., all the patients who were enrolled and randomly allocated to treatment in 
randomized clinical trials, and are included in the analysis and analyzed in the groups to which 
they were randomized) as well as by sex when data were available.  
Data Sources and Search Criteria 
The literature search was performed using Ovid® (searching MEDLINE and EMBASE 
databases), and clinicaltrials.gov. The initial database search included articles published through 
March 2016. The following terms were used to search titles and abstracts for the following 
associations using Ovid®: “depression OR MDD”; “antidepressant OR antidepressive agents”; 
“randomized AND double-blind”; and “sexual dysfunction OR sexual function OR libido.” Each 
search result linked to include all associations. Clinicaltrials.gov was searched using the 
following terms: “depression AND antidepressant AND randomized AND sexual.” Only 
interventional studies and studies with results were included. The Food and Drug Administration 
(FDA) summary basis of approval documents were reviewed for sexual functioning data via 
validated questionnaires for the following commonly prescribed antidepressants: duloxetine, 
venlafaxine, desvenlafaxine, buproprion, escitalopram, sertraline, fluoxetine, vilazodone, and 
vortioxetine.  
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Study Selection 
Typical Study Characteristics 
 The typical studies that met the criteria below were randomized, double-blind, placebo-
controlled studies of the efficacy or tolerability of at least one approved antidepressant. Many of 
the studies also included an active-control (an approved antidepressant) in addition to the test 
antidepressant. The patient population was acute major depressive disorder (MDD) patients who 
were experiencing a major depressive episode. Eligible studies included a proactive 
questionnaire assessing patient sexual functioning at baseline prior to study interventional 
treatment, and at least one timepoint post-treatment. Based on the criteria of the questionnaire, 
patients were categorized as having normal or abnormal sexual functioning prior to treatment 
and at one or more post-baseline timepoints. Most studies included a change from baseline total 
score on the sexual functioning scale. Studies were placebo-controlled to allow comparison of 
active treatment to no treatment. The primary objective of most studies was efficacy of the 
antidepressant on depressive symptoms, with sexual functioning being assessed as a tolerability 
endpoint. 
Study Selection Process and Criteria 
 Two trained reviewers (including the author) independently screened the abstracts and full 
texts articles for eligibility of studies identified by the initial search criteria. The screening 
process included two steps: an initial review of the titles and abstracts followed by a review of 
the full text of studies that meet the initial screening criteria. A third party reviewed any 
disagreements and resolved.  
The following selection criteria were applied. 
 
17 
 
Studies were included based on the following criteria: 
1. Study was randomized, double-blind, placebo-controlled antidepressant interventional 
study. 
2. Study included human patients at least 18 years of age who are being treated for 
depression. 
3. Study included only monotherapy antidepressant interventions (i.e., studies examining 
combination therapies were excluded to minimize confounding factors). 
4. Study assessed sexual dysfunction/functioning through the use of a validated sexual 
functioning questionnaire. 
5. Study evaluated only antidepressants approved by FDA for the treatment of depression.  
6. Sexual functioning was assessed at screening/baseline and at least one post-baseline 
assessment during antidepressant treatment. 
7. Study evaluated the safety/tolerability and/or efficacy of an antidepressant. 
8. Study evaluated antidepressant doses within the approved efficacious dose range; 
however, the study could have been positive, negative or failed in terms of efficacy in the 
treatment of depression.  
9. Treatment period of study was at least 6 weeks duration. 
10. Publication was in English. 
Studies were excluded based on the following criteria: 
1. Study identified antidepressant intervention by drug class, but not antidepressant name. 
2. Study evaluated patients with sexual dysfunction not related to antidepressants or 
depression, e.g., study evaluated a comorbid condition associated with sexual 
dysfunction. 
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3. Study included patients who had conditions, or were taking medications known to affect 
sexual functioning, other than depression and antidepressants. 
4. Study was reported only in abstract form.  
Studies for which both reviewers agreed did not meet selection criteria were excluded. 
Quality Assessment 
The risk of bias was assessed by two independent reviewers (including the author) utilizing the 
criteria developed by the Cochrane Collaboration (Higgins et al., 2011). An assignment of “low”, 
“unclear” or “high” risk of bias was applied to the following domains: Sequence generation, 
allocation concealment, blinding of participants, personnel and outcome assessors, incomplete 
outcome data, selective outcome reporting, and other sources of bias (see Table 1). Any 
disagreements on assessments were resolved between the reviewers by consensus.   
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Table 1. Cochrane Collaboration’s tool for assessing risk of bias 
Type of bias  Description  Relevant domains in the 
Collaboration’s ‘Risk of bias’ 
tool  
Selection bias Systematic differences between 
baseline characteristics of the 
groups that are compared 
• Sequence generation 
• Allocation concealment 
Performance bias Systematic differences between 
groups in the care that is 
provided, or in exposure to 
factors other than the 
interventions of interest 
• Blinding of participants, 
personnel and outcome assessors 
• Other potential threats to 
validity 
Attrition bias Systematic differences between 
groups in withdrawals from a 
study 
•Incomplete outcome data 
• Blinding of participants, 
personnel and outcome assessors 
Detection bias Systematic differences between 
groups in how outcomes are 
determined 
•Blinding of participants, 
personnel and outcome assessors 
• Other potential threats to 
validity 
Reporting bias Systematic differences between 
reported and unreported findings 
•Selective outcome reporting 
Other bias Any important concerns not 
covered in the other domains of 
the tool 
•Bias due to problems not 
covered elsewhere 
 
 The following data were extracted from the sources: (a) study population and demographic 
information, (b) participant eligibility criteria, (c) study design, duration and sample size, (d) 
method of randomization, (e) method of maintenance of blind, (f) intervention and dose, (g) 
patient disposition (completion, withdrawals, and reason for withdrawal), (h) sexual functioning 
assessment tool, (i) incidence of sexual dysfunction, (j) sexual functioning assessment tool mean 
total score, where available, (k) percent patients who have shifted from normal to abnormal 
sexual functioning, where available, and (l) antidepressant treatment effect. Further details are 
outlined in the coding manual found in Appendix A. 
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 The author coded the data for all the studies and an independent trained coder coded a 20% 
sample of the studies meeting criteria. Any discrepancies were discussed and resolved between 
the author and independent coder. 
Outcome Measures 
Primary Outcomes 
 The primary outcome is the standardized mean effect for sexual dysfunction for each 
antidepressant versus placebo as assessed by validated sexual functioning questionnaires. 
Secondary Outcomes 
 The following secondary outcomes were examined: 
1. Odds ratio for developing sexual dysfunction of each antidepressant versus placebo as 
assessed by validated sexual functioning questionnaires.  
2. Assessment of differences by gender, and by phases of the sexual response cycle, where 
data were available. 
Sexual Dysfunction Assessment Tools 
In clinical research trials, the most frequently used scales for assessing sexual functioning 
associated with antidepressant use are the Arizona Sexual Experiences Scale (ASEX) and 
Changes in Sexual Functioning Questionnaire (CSFQ); however, several other scales have been 
utilized to a lesser extent and reported in the literature. The ASEX and CSFQ scales are 
summarized below, and examples of each of the scales described below are listed in Appendix B.  
Arizona Sexual Experiences Scale (ASEX) 
 The ASEX is a brief self-report or clinician-administered scale with items assessing five core 
domains of sexual functioning: drive, arousal, penile erection/vaginal lubrication, ability to 
achieve orgasm and satisfaction from orgasm (McGahuey et al., 2000). Each of the five 
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questions are rated on a 6-point Likert scale ranging from hyperfunction (1) to hypofunction (6) 
with a total score range of 5-30. Higher scores indicate worse sexual functioning. The third 
question differs in the male and female version and relates to penile erection or vaginal 
lubrication. The ASEX was designed to be simple and easy to use, and to assess sexual activity 
regardless of the availability of a sexual partner. An ASEX score of ≥19, or any 1-item score ≥5, 
or any 3-item scores ≥4 indicates a high probability of sexual dysfunction. The reliability and 
validity of the ASEX was examined in 38 healthy control and 58 psychiatric patients aged 18 
years and older. The Cronbach’s alpha coefficient for the ASEX was .9055. The test–retest 
reliability for the ASEX was also calculated (for patients, r = .801, p < .01, for controls, r = .892, 
p < .01). The validity of the ASEX was tested against another validated questionnaire that 
included assessment of sexual functioning. Further details on the reliability and validity of the 
ASEX can be found in McGahuey et al., 2000. Sexual functioning data from the ASEX are 
typically reported as rates of normal/abnormal sexual functioning and rates of patients 
developing sexual dysfunction post-treatment. Total score changes over time are also reported; 
however, this is only possible when all five questions are answered. 
Changes in Sexual Functioning Questionnaire (CSFQ)   
 The CSFQ is a self-report or clinician-administered scale that contains 36 items (men) and 35 
items (women), which assesses five domains of sexual functioning (sexual desire/frequency, 
sexual desire/interest, pleasure, arousal, and orgasm), and three phases of the sexual response 
cycle (desire, arousal and orgasm) (Clayton et al., 1997). The first 21 items apply to both men 
and women. Items are rated on a 5-point Likert scale where a higher score reflects better sexual 
functioning. The CSFQ was designed to differentiate between people who have had life-long 
poor sexual functioning and those who have developed sexual dysfunction after normal 
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functioning. A shorter 14-item version of this scale, the CSFQ-14, was developed to more 
efficiently assess the domains of sexual functioning evaluated by the longer version and has 
demonstrated good construct validity and internal reliability. The reliability and validity of the 
CSFQ-14 was examined in 6, 286 patients evaluated for depression. Cronbach’s alpha coefficient 
was calculated for the whole sample and for each sex separately. Cronbach’s alpha for the total 
CSFQ-14 score was .90 for the female version and .89 for the male version. Further details of the 
reliability and of the validity can be found in Keller et al., 2006.  
 A score of less than 47 for men and less than 41 for women indicates sexual dysfunction on 
the CSFQ-14 scale (Keller et al., 2006). The CSFQ-14 is more commonly used that the longer 
version, and has been the choice for use in clinical trials and other studies reported in the 
literature. Sexual functioning data per the CSFQ-14 are reported as rates of normal/abnormal 
sexual functioning, the rate of patients developing sexual dysfunction post-treatment, and total 
scores or scale subscores changes. 
 The methods of sexual functioning assessment have varied widely, including by patient 
interview, reporting of adverse events, and various questionnaires. This varying format of 
inquiry makes determination of the impact of a given antidepressant on sexual functioning 
difficult to assess across studies. For example, reports of adverse events only are known to be 
under-reported and unreliable, and are therefore not helpful in differentiation effects compared to 
placebo. Structured questionnaires that assess the same construct, i.e., domains related to the 
sexual response cycle, yield more informative data. For example, the ASEX, CSFQ, and 
Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) assess aspects of desire, 
arousal and orgasm (phases of the sexual response cycle). These scales, which have also been 
validated, can be used to calculate scores that indicate the level of impaired sexual functioning. 
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In addition, the ability to calculate abnormal and normal sexual functioning from scale scores 
provides a more reliable assessment of odds ratios compared to calculations using adverse event 
reporting.  
Data Analysis 
The data were analyzed using SPSS (version 25) and specialized meta-analysis macros written 
specifically for this program (Lipsey & Wilson, 2001).  
Effect Size Metrics 
 Odds ratios (ORs) were used as the effect size metric for binary outcomes and standardized 
mean difference effect sizes were used as the effect size metric for continuous outcomes for each 
antidepressant. Effect sizes were coded such that the larger effect size represents positive 
outcomes (i.e., better sexual functioning compared to placebo).  
 Odds ratios were calculated for overall rates of sexual dysfunction (percent of patients with 
abnormal sexual dysfunction after antidepressant treatment). The logged odds-ratio was 
calculated as follows: 
 = ln(OR)   
 
 
Where ln(OR) is the natural log of the odds ratio, a and b are the frequencies of normal and 
abnormal sexual functioning in the treatment group, and c and d are the respective frequencies in 
the comparison (placebo) group.   
The sampling variance of the logarithm of the odds ratios was calculated as follows: 
 () = 1 +
1
 +
1
 +
1
 
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 The standardized mean difference effect for each antidepressant were used as the effect size 
metric for sexual functioning scale scores after treatment. Mean effect sizes were calculated 
following the independent groups pretest-posttest design in which two groups of participants are 
assigned to alternate treatment conditions (e.g., experimental and control) (Becker, 1988; Morris 
& DeShon, 2002; Morris, 2008). The majority of the studies reported mean change or gain scores 
(i.e., the difference between pretest and posttest sexual functioning scores) and standard 
deviations of the change for each treatment group; therefore, standardized effect sizes for each 
comparison (antidepressant versus control) within study were calculated using mean change 
scores and standard deviations of the change. None of the studies reported the population 
correlation between pretest and posttest scores, so the correlation was assumed to be 0.8.  
Standardized effect sizes were calculated using an online calculator companion to Practical 
Meta-Analysis by Mark W. Lipsey and David B. Wilson, 2001, which can be accessed at the 
following web address: http://www.campbellcollaboration.org/escalc/html/EffectSizeCalculator-
Home.php. Formulas for the effect size calculations can be found in Morris and DeShon (2002).   
Because the standardized effect size can be upwardly biased in small samples, the standardized 
effect size was adjusted using the following Hedges correction (Hedges, 1981): 
 = 1 − 34 − 9   
Where N is the total sample size and  is the unadjusted effect size.  
All effect sizes were reported using a 95% confidence interval. 
 In studies that included treatment groups with more than one effective dose of a particular 
antidepressant, effect sizes were calculated within study by dose and pooled to create the mean 
effect size for that antidepressant, as there were insufficient studies to calculate effect sizes by 
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dose. Some studies compared different antidepressants (e.g., duloxetine and paroxetine versus 
placebo) to the same placebo arm; therefore, some effect sizes utilized multiple comparisons to 
placebo. This was also true for antidepressants of different doses in the same study.    
Missing Data 
 Data from the intent-to-treat analyses were used. When analysis from intent-to-treat (ITT) 
population was not available, the analysis from patients who completed study were used. When 
information needed to complete the primary measures was missing, additional information was 
gathered by contacting the authors, via the clinicaltrials.gov or via pharmaceutical company 
websites. Review of FDA summary basis of approvals did not reveal any additional data.  
Descriptive Statistics 
 Descriptive statistics were used to summarize the current state of the literature and highlight 
gaps in research on sexual dysfunction associated with antidepressant treatment. Descriptives 
were synthesized across primary studies on the characteristics of methodology, participants, type 
of intervention, assessment scale(s) used and outcome. 
Sensitivity Analysis 
 The data were evaluated for outliers. The effect size distributions were evaluated for outliers 
using Tukey’s (1977) inner fence criterion. The distribution of sample sizes as well as weights 
(for odds-ratios) were examined for any extreme values. Publication bias was evaluated using 
funnel plots. Underrepresentation of unpublished studies, which are more likely to have 
unfavorable results, can substantially bias effect size estimates (Borenstein et al., 2009). All 
reasonable attempts were made to include unpublished research such as accessing 
clinicaltrials.gov, and pharmaceutical websites and FDA summary basis of approval documents.  
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Synthesis of Effect Sizes and Assessment of Heterogeneity  
 The distribution of effect sizes across all antidepressants was examined descriptively using 
forest plots. Random effects models were planned to account for heterogeneity between studies 
given the likely variation in study characteristics and for the importance of supporting 
generalization of findings beyond the included studies (Borenstein et al., 2009). Random effects 
weighed mean effect sizes and 95% confidence intervals for each study were calculated if 
sufficient comparisons existed. The random effects variance component was calculated using the 
DerSimonian/Laird estimate (DerSimonian & Laird, 1986). Using random effects models allows 
for the accounting for within study sampling variance and between study variability; however, if 
the number of studies is small it is not possible to obtain a good estimate of the random effects 
variance. Because mean effect sizes were calculated for each antidepressant, there were too few 
comparisons to estimate the random effects variance for each antidepressant; therefore, the data 
calculated using the fixed effects model is presented. 
 Assessment of heterogeneity of the effect size differences between studies was evaluated 
using both the χ2 and I2 statistics. Tests of heterogeneity are a measure of the variability in the 
distribution of effect sizes, and in a homogeneous distribution, the amount of variability is no 
greater than that which is expected due to sampling error alone. The null hypothesis of 
homogeneity was rejected in the case of a χ2 value with p<0.05. For interpretation of the I2 
statistic, the guidance suggested in The Cochrane Handbook was used for substantial to 
considerable heterogeneity (i.e., I2 more than 50%). Discussion is included for heterogeneity in 
results found. 
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Moderator Analyses 
 A number of moderator analyses were planned if there were sufficient studies eligible. 
Significant variability in effects (i.e., the Q statistic indicates significant heterogeneity in effect 
sizes) was expected. It is known that many antidepressants have negative effects on sexual 
functioning, and antidepressants may differ in these effects. Thus, separate meta-analyses were 
conducted for each antidepressant. In addition, the effects of antidepressants often differ by 
gender and potentially by type of sexual functioning scale. 
 Moderator analyses were planned for gender and sexual functioning scale; however, only 
gender differences were examined since there was insufficient number of studies and data to 
examine differences by sexual functioning scale, or any other study characteristic. Gender 
differences are discussed in the Results section. 
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CHAPTER FOUR 
RESULTS  
Literature Search, Identification and Selection 
Figure 1 shows a flow diagram summary of the search and selection of all data sources evaluated 
for this meta-analysis. In the initial search, 320 reports were identified, with 240 being identified 
through searching within the electronic database, Ovid. Ovid allows for removal of duplicates 
during the search; therefore, the 240 sources reflect removal of duplicates. An additional 80 
reports were identified through other means, such as, Clinicaltrials.gov, citation searches, 
pharmaceutical websites with study results posted, and the FDA summary basis of approval 
documents. Abstracts (or titles when abstracts were not available) were screened for initial 
relevance. Of the 320 screened, 222 were excluded that were clearly not eligible for inclusion. 
Full text copies were obtained or retrieved for the remaining 98 reports and further reviewed for 
inclusion. Of these, 79 were deemed not eligible with the primary reasons being irrelevant or 
simply wrong study design, and no sexual functioning questionnaire used. Details of the reasons 
for exclusion are provided in Figure 1. The remaining 19 reports were used for coding of the 17 
eligible studies. During the coding process, an additional 3 sources of data were obtained in 
order to complete the required data for calculation of effects sizes and odds ratios. Two of the 
reports included pooled data on two or more studies. Data sources for the original study reports 
were obtained if possible.  
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Figure 1. Flow diagram, summary of search and selection 
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Characteristics of Included Studies 
The details of the eligible studies are provided in Table 2. The 17 eligible studies included 9,475 
men and women who were diagnosed with acute major depressive disorder (MDD). The total 
patients included in the sample excluded Study 5, which was pooled data from studies 6 and 7, 
but included pooled Study 10 and not studies 16-18. Study 10 included data from 4 of the Lilly 
studies, but only 3 of the 4 Lilly studies referenced in study 10 were available as individual 
reports. All but two studies had 8-week treatment periods, with the remaining two having a 10-
week and 12-week treatment period. All 17 studies were placebo-controlled as per inclusion 
criteria to allow for consistent comparison of mean effect sizes; however, 13 of the studies also 
included more than one antidepressant in addition to placebo allowing for multiple calculation of 
effect sizes versus placebo within the same trial, potentially reducing inter-study variability. 
However, multiple comparisons to placebo also introduces dependencies in effect sizes. As 
mentioned, study duration was also consistent, with 15 of the 17 studies having an 8-week 
treatment period. All of the eligible studies were randomized controlled trials funded by 
pharmaceutical companies likely because the inclusion criteria required that the sexual 
functioning scale utilized be validated, and pharmaceutical companies tend to prioritize the use 
of validated scales, primarily for regulatory reasons. The randomization schemes for these 
studies were centrally generated and treatment assignment was allocated in a double-blind 
fashion with investigative sites utilizing either interactive voice response system or a web-based 
system.  
 Only studies that utilized the ASEX and CSFQ-14 were included in the analysis as they 
contained the necessary data to calculate mean effect sizes from total score and odd ratios from 
determination of normal and abnormal sexual functioning. The Psychotropic-Related Sexual 
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Dysfunction Questionnaire (PRSexDQ) has been predominantly used in schizophrenia 
populations and results in depressed populations were published in Spanish; therefore, no studies 
that utilized this scale met eligibility criteria. Six studies utilized the CSFQ-14 scale and 11 used 
the ASEX scale.  
 Publication year ranged from 2004 through 2015 and reflected the fact that inclusion of 
validated sexual functioning questionnaires in studies is fairly recent. Most (81%) of the studies 
were conducted in the United States. The majority (64%) of participants were women and ranged 
from 56% to 74%, which is consistent with the prevalence of women versus men with MDD in 
the overall population. Participants were predominantly Caucasian (80%) and African American 
(17%). The slightly higher percentage of Caucasians in the overall population reflects the 
inclusion of studies with sites in Europe, which enrolled over 95% Caucasians. The mean age in 
the overall population of studies combined was 42 years. 
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Table 2. Summary of study design and references. 
Study 
identifier 
 
Antidepressant Dose per arm 
(mg/QD) 
Number of 
Subjects 
(ITT) 
Study Design Time of 
endpoint 
Sexual 
Function 
tool 
Endpoints 
 
Reported by 
sex 
1.Clayton et 
al., 2006 (a) 
 
Buproprion  
 
Escitalopram  
 
Placebo 
300-450 mg 
flexible 
10-20 mg 
flexible 
 NA 
133 
 
130 
 
127 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy  
Week 8 CSFQ-14 Mean 
change 
from BL 
Male/female 
combined 
2.Clayton et 
al., 2006 (a) 
Buproprion  
 
Escitalopram  
 
Placebo 
300-450 mg 
flexible 
10-20 mg 
flexible 
NA 
129 
 
130 
 
125 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 CSFQ-14 Mean 
change 
from BL 
Male/female 
combined 
3.Clayton et 
al., 2007 
Duloxetine 
Escitalopram 
Placebo 
60 mg fixed 
10 mg fixed 
NA 
67M, 118F 
62M, 145F 
37M, 59F 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 CSFQ-14 Mean 
change 
from BL; 
percent 
SD 
Male/female 
reported 
separately; 
combined 
calculated 
4.Clayton, 
Reddy, et 
al., 2013; 
Dunlop, et 
al., 2011 
Desvenlafaxine 
Placebo 
50 mg fixed 
NA 
82M, 157F 
37M, 74F 
Rand, DB, 
PBO 
controlled, 
efficacy 
Week 12 ASEX Mean at 
endpoint; 
percent 
SD 
Male/female 
reported 
separately; 
combined 
calculated 
5.Clayton, 
Kennedy, et 
al., 2013 (b) 
Vilazodone 
Placebo 
40 mg fixed 
NA 
 
159M, 241F 
174M, 227F 
Pooled SD 
data from 
studies 6 and 
7 
Week 8 ASEX, 
CSFQ-14 
Percent 
SD 
Male/female 
reported 
separately; 
combined 
calculated 
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Study 
identifier 
 
Antidepressant Dose per arm 
(mg/QD) 
Number of 
Subjects 
(ITT) 
Study Design Time of 
endpoint 
Sexual 
Function 
tool 
Endpoints 
 
Reported by 
sex 
6.Clayton, 
Kennedy, et 
al., 2013 
(b); Rickels 
et al., 2009 
Vilazodone 
Placebo 
40 mg fixed 
NA 
 
72M, 124F 
72M, 124 F 
Rand, DB, 
PBO 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL 
Male/female 
reported 
separately; 
combined 
calculated 
7.Clayton, 
Kennedy et 
al., 2013 
(b); Khan et 
al., 2011 
Vilazodone 
Placebo 
40 mg fixed 
NA 
 
87M, 119F 
102M, 108F 
Rand, DB, 
PBO 
controlled, 
efficacy 
Week 8 CSFQ-14 Mean 
change 
from BL 
Male/female 
reported 
separately; 
combined 
calculated 
8.Clayton, 
Tourian, et 
al, 2015 (c) 
Desvenlafaxine 
Desvenlafaxine 
Placebo 
50 mg fixed 
100 mg fixed 
NA 
138M, 300F 
149M, 307F 
135M, 300F 
Rand, DB, 
PBO 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL, 
percent 
SD 
Male/female 
reported 
separately 
and 
combined 
9.Clayton, 
Gommoll, 
et al., 2015; 
Mathews et 
al., 2015 
Vilazodone 
Vilazodone 
Citalopram 
Placebo 
20 mg fixed 
40 mg fixed 
40 mg fixed 
NA 
201M, 267F 
192M, 259F 
205M, 257F 
212M, 264F 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 10 CSFQ-14 Mean 
change 
from BL, 
percent 
SD 
Male/female 
reported 
separately 
and 
combined 
10.Nelson 
et al., 2006 
(d) 
Duloxetine 
 
Paroxetine 
 
Placebo 
40-120 mg 
fixed 
20 mg fixed 
 
NA 
736 
 
359 
 
371 
Pooled data 
from 4 Rand, 
DB, PBO, 
and active 
controlled, 
efficacy; 
including 
studies 16-18 
Week 8 ASEX Percent 
SD 
Male/female 
combined 
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Study 
identifier 
 
Antidepressant Dose per arm 
(mg/QD) 
Number of 
Subjects 
(ITT) 
Study Design Time of 
endpoint 
Sexual 
Function 
tool 
Endpoints 
 
Reported by 
sex 
11.Hewett 
et al., 2010 
Buproprion 
 
Venlafaxine 
 
Placebo 
150-300 mg 
flexible 
75-150 mg 
flexible 
NA 
193 
 
202 
 
186 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 CSFQ-14 Mean 
change 
from BL 
Male and 
female 
combined 
12.Bouleng
er et al., 
2014; 
Clinicaltrial
s.gov 
NCT011409
06 
Vortioxetine 
Vortioxetine 
Duloxetine 
Placebo 
15 mg fixed 
20 mg fixed 
60 mg fixed 
NA 
147 
148 
144 
156 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL 
Male/female 
combined 
13.Mahable
shwarkar, 
Jacobsen, 
Chen et al., 
2015 (e) 
Vortioxetine 
Vortioxetine 
Duloxetine 
Placebo 
15 mg fixed 
20 mg fixed 
60 mg fixed 
NA 
31M, 81F 
25M, 86F 
28M, 85F 
35M, 93F 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL, 
percent 
SD 
Male/female 
reported 
separately 
and 
combined 
14.Jacobsen 
et al., 2015 
(e) 
Vortioxetine 
Vortioxetine 
Placebo 
10 mg fixed 
20 mg fixed 
NA 
30M, 93F 
31M, 89F 
41M, 96F 
Rand, DB, 
PBO 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL, 
percent 
SD 
Male/female 
reported 
separately 
and 
combined 
15.Mahable
shwarkar, 
Jacobsen, 
Serenko et 
al., 2015 (e) 
Vortioxetine 
Vortioxetine 
Placebo 
10 mg fixed 
15 mg fixed 
NA 
 
38M, 91F 
33M, 88F 
44M, 89F 
Rand, DB, 
PBO 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL, 
percent 
SD 
Male/female 
reported 
separately 
and 
combined 
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Study 
identifier 
 
Antidepressant Dose per arm 
(mg/QD) 
Number of 
Subjects 
(ITT) 
Study Design Time of 
endpoint 
Sexual 
Function 
tool 
Endpoints 
 
Reported by 
sex 
16.https://w
ww.lilly.co
m/clinical-
study-
report-csr-
synopses 
F1J-MC-
HMATa 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
40 mg fixed 
80 mg fixed 
20 mg fixed 
NA 
58 
52 
44 
47 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL, 
percent 
SD in 
pooled 
Study 10 
Male/female 
combined 
17.https://w
ww.lilly.co
m/clinical-
study-
report-csr-
synopses 
F1J-MC-
HMATb 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
40 mg fixed 
80 mg fixed 
20 mg fixed 
NA 
50 
45 
48 
49 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL, 
percent 
SD in 
pooled 
Study 10 
Male/female 
combined 
18.https://w
ww.lilly.co
m/clinical-
study-
report-csr-
synopses 
F1J-MC-
HMAYa 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
80 mg fixed 
120 mg fixed 
20 mg fixed 
NA 
19M, 40F 
21M, 32F 
17M, 39F 
17M, 31F 
 
Rand, DB, 
PBO and 
active 
controlled, 
efficacy 
Week 8 ASEX Mean 
change 
from BL, 
percent 
SD in 
pooled 
Study 10 
Male/female 
reported 
separately 
and 
combined 
ITT = Intent-to-treat; QD = once daily; Rand = randomized; DB = double-blind; PBO = placebo; CSFQ-14 = Changes in Sexual Functioning Questionnaire;  
BL = Baseline; SD = sexual dysfunction; ASEX = Arizona Sexual Experiences Scale; M = male; F = female 
 
(a) Two studies of identical design were reported in the same publication. 
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(b) Clayton, Kennedy et al. (2013) report sexual functioning change scores for 2 separate studies and pooled data for percent patients with and without sexual 
dysfunction at endpoint (identified as studies 5, 6, and 7 for clarity). 
 
(c) Number of patients per group is different for ASEX total score change from baseline and for percent patients with and without sexual dysfunction. The 
larger number is reported here. 
 
(d) Nelson et al. (2006) reports percent patients with and without sexual dysfunction for 4 studies pooled, however, the sexual functioning change scores were 
obtained from 3 of those studies from clinical trial synopses provided on the pharmaceutical companies website (studies 16, 17 and 18). 
 
(e) Additional data was provided by one of the publication authors in order to calculate mean effect scores. 
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Study Level Demographic Characteristics 
 Baseline demographic characteristics by study are listed in Table 3. Pooled studies 5 and 10 
are not included as they are represented by individual studies as described in Table 2. Mean 
Montgomery–Åsberg Depression Rating Scale (MADRS) total scores, where included, indicated 
that the population enrolled was moderate to severely depressed (MADRS total score >30). 
Three studies (16, 17 and 18) enrolled mildly depressed patients with mean MADRS total scores 
of 22 and 23. Hamilton Depression Rating Scale (HAM-D) 17-item total scores were generally 
consistent with MADRS total scores with regard to severity of depression in studies where both 
were assessed. Mean baseline CSFQ-14 and ASEX total scores, where reported, indicated a 
range of patients with various levels of sexual functioning upon study entry.   
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Table 3. Baseline demographics by study. 
Study  
Identifier 
Antidepressant 
arms 
Mean 
age 
% 
Women 
Mean 
MADRS 
Mean 
HAM-D 
(b) 
Mean 
CSFQ-14 
Mean 
ASEX 
1.Clayton et 
al., 2006 (a) 
Buproprion  
Escitalopram  
Placebo 
35.7 62.0 - 24 51.5 - 
2.Clayton et 
al., 2006 (a) 
Buproprion  
Escitalopram  
Placebo 
36.6 58.0 - 23 53.4 - 
3.Clayton et 
al., 2007 
Duloxetine 
Escitalopram 
Placebo 
42.2 63.5 - 18 36.0 - 
4.Clayton, 
Reddy, et 
al., 2013; 
Dunlop, et 
al., 2011 
Desvenlafaxine 
Placebo 42.5 65.2 31 22 - 18.9 
6.Clayton, 
Kennedy, et 
al., 2013; 
Rickels et 
al., 2009 
Vilazodone 
Placebo 39.9 63.7 31 25 - 19.4 
7.Clayton, 
Kennedy et 
al., 2013; 
Khan et al., 
2011 
Vilazodone 
Placebo 41.7 53.2 32 25 42.8 - 
8.Clayton, 
Tourian, et 
al, 2015  
Desvenlafaxine 
Desvenlafaxine 
Placebo 
41.6 57.7 - 24 - 15.2 
9.Clayton, 
Gommoll, et 
al., 2015; 
Mathews et 
al., 2015 
Vilazodone 
Vilazodone 
Citalopram 
Placebo 
41.8 55.7 31 - 41.6 - 
11.Hewett 
et al., 2010 
Buproprion 
Venlafaxine 
Placebo 
44.7 67.0 30 - 36.1 - 
12.Bouleng
er et al., 
2014; 
Vortioxetine 
Vortioxetine 
Duloxetine 
Placebo 
46.7 69.6 31 - - - 
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Study  
Identifier 
Antidepressant 
arms 
Mean 
age 
% 
Women 
Mean 
MADRS 
Mean 
HAM-D 
(b) 
Mean 
CSFQ-14 
Mean 
ASEX 
Clinicaltrial
s.gov 
NCT011409
06 
13.Mahable
shwarkar, 
Jacobsen, 
Chen et al., 
2015 
Vortioxetine 
Vortioxetine 
Duloxetine 
Placebo 
42.9 72.0 32 - - - 
14.Jacobsen 
et al., 2015 
Vortioxetine 
Vortioxetine 
Placebo 
42.8 70.1 32 - - - 
15.Mahable
shwarkar, 
Jacobsen, 
Serenko et 
al., 2015 
Vortioxetine 
Vortioxetine 
Placebo 
45.0 67.5 34 - - - 
16. F1J-
MC-
HMATa, 
2004 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
43.7 65.6 22 18 - 17.9 
17. F1J-
MC-
HMATb, 
2004 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
40.5 64.0 23 18 - 16.1 
18. F1J-
MC-
HMAYa, 
2004 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
42.9 74.2 22 20 - 19.7 
MADRS = Montgomery–Åsberg Depression Rating Scale; HAM-D = Hamilton Depression Rating Scale;  
CSFQ-14 = Changes in Sexual Functioning Questionnaire; ASEX=Arizona Sexual Experiences Scale. 
 
(a) Two studies of identical design were reported in the same publication. 
 
(b) The 17-item HAM-D was used for assessment of depressive symptoms in these studies. 
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Assessment of Risk of Bias 
Each study was assessed for risk of bias utilizing the Cochrane Collaboration’s tool as outlined 
in Table 1. All studies evaluated had low risk for bias on all domains with the exception of one 
study evaluating desvenlafaxine (Clayton, Tourian et al., 2015), for reporting bias. The 
publication indicated that the ASEX total scores were only reported for patients who had been 
sexually active in the past week. Most depressed patients have some level of sexual dysfunction, 
so this reduced the sample size to 422 from 907 patients. The full 907 patients were evaluated in 
assessment of odds ratios. The article stated that the results of the subgroup for change scores 
was consistent with the analysis done for all patients; however, those data were not reported. 
Although reporting bias cannot be ruled out, the odds ratio data, which contained the entire 
sample, was consistent in direction and by sex with the standardized mean effect scores. Thus, 
the determination was made to include these data. 
Assessment of Publication Bias 
Publication bias was evaluated through the use of funnel plots. Publication bias stems from 
failing to detect unpublished studies, which are more likely to have unfavorable results, and/or 
may have small samples with greater variance, and can substantially bias effect size estimates. 
The majority of the studies included were published; however, data from 7 of the 17 studies 
came from unpublished sources, ether partially or entirely (Table 2). Of the 17 included studies, 
9 were authored by Anita Clayton, MD. Since this meta-analysis included only studies which 
utilized ASEX or CSFQ, it is not unusual for Clayton to be the author on many publications as 
she developed the CSFQ. The ASEX is an older tool and has been adopted in more studies in the 
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past, but not necessarily with inclusion of the scale developer. The ASEX and CSFQ-14 were 
both included in large studies.  
 The smallest unpublished studies included in this analysis were obtained from the Lilly 
website and included paroxetine and duloxetine. The samples sizes per arm ranged from 44 to 
59, so were not unusually small. The funnel plots for effect sizes (Figure 2) and odds ratios 
(Figure 3) are presented below. In fact in Figure 2, two observations (observation 20 
corresponding to duloxetine 80 mg in unpublished study 16, and observation 40 corresponding to 
paroxetine 20 in unpublished study 18, Lilly studies) are shown to have higher variances. 
However the sample sizes are not particularly small, so the data were included. In Figure 3, the 
funnel plot for logged odds ratios, observation 4 corresponding to desvenlafaxine 50 mg in study 
4 has a higher variance compared to other observations, but the sample size was relatively large 
(N=239), so the data were included. It should be noted that all of the publications that met 
criteria were funded by pharmaceutical companies. Individual sponsored studies tend not to be 
double-blinded, placebo-controlled studies that utilize validated sexual functioning 
questionnaires. Because no non-pharmaceutical funded studies met eligibility criteria, it is not 
known whether studies conducted similarly by individuals outside the pharma industry would 
have yielded different results in this analysis. 
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Figure 2. Funnel Plot for Sexual Functioning Standardized Mean Effect Sizes, Both Sexes 
 
Figure 3. Funnel Plot for Sexual Functioning Logged Odds Ratios, Both Sexes 
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Assessment of Outliers 
The distributions of mean effect sizes (75 cases) and logged odds ratio effect sizes (28 cases) 
were examined for outliers. Outliers were defined as values that fell more than three interquartile 
ranges (IQR) above the 75th percentile or below the 25th percentile of the distribution (Tukey, 
1977). No outliers were identified in the logged odds ratio effect size distributions. One outlier 
was identified in the mean effect size distribution, paroxetine 20 mg in men from the Lilly study 
18. Based on the literature, men taking paroxetine report more negative sexual side effects 
compared to women in general. Because of the possibility of gender effects, the data for this 
observation was included without adjustment.   
Effects on Sexual Functioning of Antidepressants versus Placebo 
Standardized mean effect sizes for each antidepressant were calculated for 13 of the 17 studies. 
Four of the studies did not provide sufficient data to calculate mean effects, e.g., study did not 
report standard deviations or standard errors, and attempts to obtain data were not successful. 
Odds ratios for developing sexual dysfunction versus placebo were calculated for 9 of the 17 
included studies based on available data. Odds ratios were only calculated for studies that 
provided normal or abnormal sexual dysfunction data that were calculated based on the accepted 
definition for the ASEX or CSFQ-14 scales. 
Standardized Effect Sizes for Mean Change Scores 
 Standardized effect sizes were calculated based on change scores (mean gains) for placebo 
and antidepressant in the 13 studies where data were reported. Table 4 lists the standardized 
mean effect sizes, standard errors, CIs, the Q statistic and its significance for each antidepressant 
versus placebo. There were insufficient eligible studies to calculate reliable mean effect sizes by 
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dose and antidepressant. Therefore, effect sizes were calculated within study by dose and pooled 
to create the mean effect size for that antidepressant, as long as the dose was in the approved 
therapeutic range. Standardized effect sizes by subscales or single items were also not calculated 
due to insufficient sample size. The Q statistic was calculated to determine if there was 
significant heterogeneity of variance. The Q statistic could not be calculated for comparisons 
between citalopram versus placebo, or for venlafaxine versus placebo because only one study 
each was eligible for inclusion in the analysis. Some subgroups by gender included only one 
study as well, so the Q statistic was not calculated (see Table 4).  
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Table 4. Mean Standardized Effect Sizes for Each Antidepressant by Sex 
Antidepressant 
Comparison 
Doses 
(mg) Sex Scale 
Num-
ber 
studies 
Effect 
Size (a) SE Q  
Significance 
of Q CI Low CI High 
Buproprion XL  150 – 450 Both CSFQ 3 0.034 0.042 0.200 0.905 -0.049 0.117 
Citalopram  40  Both CSFQ 1 -0.087 0.062  - -0.208 0.034 
Citalopram  40  Men CSFQ 1 -0.117 0.095  - -0.304 0.070 
Citalopram  40 Women CSFQ 1 -0.062 0.082  - -0.222 0.099 
Desvenlafaxine 50 and 100  Both ASEX 3 0.025 0.043 3.305 0.192 -0.060 0.110 
Desvenlafaxine  50 and 100 Men ASEX 3 -0.095 0.066 0.136 0.934 -0.224 0.034 
Desvenlafaxine  50 and 100 Women ASEX 3 0.086 0.066 0.937 0.626 -0.044 0.215 
Duloxetine (b) 40-120 Both ASEX, CSFQ 9 -0.018 0.034 22.16 *0.005 -0.085 0.048 
Duloxetine  40-120 Men ASEX, CSFQ 4 -0.028 0.083 1.717 0.633 -0.191 0.135 
Duloxetine  40-120 Women ASEX, CSFQ 4 -0.080 0.059 3.312 0.346 -0.194 0.035 
Escitalopram  20 Both CSFQ 3 -0.190 0.046 0.061 0.970 -0.280 -0.101 
Escitalopram  20 Men CSFQ 1 -0.080 0.132  - -0.338 0.177 
Escitalopram  20 Women CSFQ 1 -0.290 0.099  - -0.483 -0.097 
Paroxetine  20 Both ASEX 3 -0.169 0.073 1.152 0.562 -0.312 -0.027 
Paroxetine  20 Men ASEX 1 -0.529 0.226  - -0.972 -0.085 
Paroxetine  20 Women ASEX 1 -0.148 0.153  - -0.448 0.151 
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Antidepressant 
Comparison 
Doses 
(mg) Sex Scale 
Num-
ber 
studies 
Effect 
Size (a) SE Q  
Significance 
of Q CI Low CI High 
Venlafaxine  75-150 Both CSFQ 1 0.041 0.064  - -0.084 0.167 
Vilazodone  20-40 Both ASEX, CSFQ 4 -0.015 0.032 1.133 0.769 -0.077 0.046 
Vilazodone  20-40 Men ASEX, CSFQ 4 -0.144 0.048 1.120 0.772 -0.238 -0.049 
Vilazodone  20-40 Women ASEX, CSFQ 4 0.048 0.042 2.754 0.431 -0.033 0.129 
Vortioxetine  10-20 Both ASEX 8 0.046 0.028 4.838 0.680 -0.008 0.100 
Vortioxetine  10-20 Men ASEX 6 0.113 0.066 1.715 0.887 -0.016 0.241 
Vortioxetine  10-20 Women ASEX 6 0.018 0.039 3.165 0.675 -0.057 0.094 
CSFQ = Changes in Sexual Functioning Questionnaire; ASEX = Arizona Sexual Experiences Scale; ES = effect size; SE = standard error; Q = the Q statistic; 
CI = confidence interval 
 
(a) Decreases indicate worsening of sexual functioning. 
 
(b) The Q statistic for heterogeneity of variance was significant for the standardized mean effect size for both sexes combined. I2 statistic for this effect size and 
was 59%.  
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 Random effects models were planned to account for heterogeneity between studies; however, 
in many cases the number of studies for each antidepressant was too small to calculate a reliable 
random variance component (see Table 4). In cases where there were 3 or more comparisons, 
random effects weighted mean effect sizes and 95% confidence intervals for each study were 
calculated. A total of 15 comparisons included 3 or more studies and of these, only 3 
comparisons had population variance components that were different than 0. These comparisons 
were for desvenlafaxine versus placebo, and for duloxetine versus placebo for both sexes 
combined, and for duloxetine versus placebo for women. Overall there were no directional 
changes in the point estimates for random effects weighted means for these 3 comparisons. 
Arguably, comparisons that include even 3 studies are likely to be too small to calculate random 
effects variance, and in fact most of the random variance components in these cases were 
negative, thus 0.   
 The studies included in this meta-analysis were very similar in conduct due to the strict 
inclusion criteria, e.g., randomized, placebo-controlled, acute MDD population, similar age 
range and use of validated sexual functioning scale; therefore, it is appropriate to present the data 
using a fixed-effect model.  
 The standardized mean effect size, standard error, Q statistic and its significance, and 95% 
confidence intervals were also calculated for each study (see Appendix C). The mean effect sizes 
were calculated by combining all active arms within the study, if more than one was included, 
compared with placebo. Effect sizes were generally small with approximately half were negative 
and half positive. Because antidepressants are known to have varying effects on sexual 
functioning, from minimal (e.g., buproprion) to significant (e.g., paroxetine), the overall effect 
sizes by studies was not particularly informative as many included more than one antidepressant. 
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 Figures 4-6 plot the mean standardized effect sizes for each antidepressant versus placebo for 
both sexes combined and by sex. 
Figure 4. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus 
Placebo, Both Sexes Combined
 
 Figure 4 shows forest plots for each antidepressant versus placebo for both sexes combined. 
Only one comparison has significant heterogeneity (Q=22.16; p=0.005): duloxetine, both sexes 
combined (see Table 3). The I2 statistic was calculated (59%) for this effect size. Given that the 
I2 assessment for heterogeneity was greater than 50%, the individual effect sizes for this 
comparison were evaluated. The comparison between duloxetine and placebo included the 
highest number of studies in this analysis, which may contribute to the larger range of effect 
sizes. In addition, this comparison included several dose groups for duloxetine (40 mg, 60 mg, 
80 mg and 120 mg daily), and the level of sexual dysfunction may be dose-dependent. Review of 
the individual effect sizes showed that typically lower dose studies with duloxetine had less 
negative effects; however, it also appeared to be related to gender.  Citalopram, duloxetine, 
Worse than Placebo Better than Placebo 
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escitalopram, paroxetine and vilazodone have point estimates that are worse than placebo; 
however, escitalopram and paroxetine are the only antidepressants that are significantly worse 
than placebo for both sexes combined. The point estimate for citalopram is somewhat higher, but 
the difference is not significant. The remaining antidepressants do not differ significantly versus 
placebo when both sexes are combined.  
 Mean effect sizes were calculated by sex as it was suspected to be a moderator of sexual 
dysfunction and antidepressant. Figures 5 and 6 show forest plots for each antidepressant for 
which data by sex were available. The Q statistic was not significant for any antidepressant 
comparison for the subgroup gender. In men Figure 5), significant differences are found between 
paroxetine and placebo, similar to both sexes combined, but while the point estimate for 
escitalopram is worse than placebo, it is not significantly different. However, in men, vilazadone 
is significantly worse than placebo, but the confidence intervals are very narrow and the point 
estimate is similar to desvenlafaxine and citalopram, which are not significantly worse than 
placebo. The relatively narrow confidence intervals should be taken into consideration when 
assessing the clinical relevance of the significance of this effect.  
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Figure 5. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus 
Placebo, Men 
 
 
 
 In women (Figure 6) escitalopram is the only antidepressant significantly worse than 
placebo; however, point estimates for paroxetine, citalopram and duloxetine are worse than 
placebo, but not significantly. The confidence intervals for the point estimate for paroxetine are 
wide for both men and women; however, it is clear that sexual functioning for both men and 
women on paroxetine is worse than placebo (even in women where the CI does not cross 0). 
While duloxetine was not significantly worse than placebo in men or women, the point estimate 
for women was worse than for men, which likely contributed to the heterogeneity in the 
combined sex group where the Q statistic was significant. 
Worse than Placebo Better than Placebo 
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Figure 6. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus 
Placebo, Women  
 
 
 Finally, Figure 7 shows the standardized effects sizes for each antidepressant versus placebo 
by men and women, and by combined sexes together in one figure. Gender differences are most 
striking for paroxetine and escitalopram. Men are more negatively impacted with treatment of 
paroxetine than women, but women are more negatively impacted by treatment with 
escitalopram than men.  
 
Worse than Placebo Better than Placebo 
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Figure 7. Sexual Functioning Mean Standardized Effect Sizes with Antidepressants versus 
Placebo, by Sex 
 
 
 
Odds Ratios for Developing Sexual Dysfunction 
 Odds ratios were calculated from the proportion of patients with and without sexual 
dysfunction, per ASEX or CSFQ-14 scale definition, at study endpoint. Table 5 lists the mean 
standardized odds ratios, standard errors, CIs, the Q statistic and its significance for each 
antidepressant versus placebo. There were insufficient eligible studies to calculate reliable mean 
effect sizes by dose and antidepressant. Therefore, effect sizes were calculated within study by 
dose and pooled to create the mean effect size for that antidepressant, as long as the dose was in 
Worse than Placebo Better than Placebo 
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the approved therapeutic range. The Q statistic was not significant for any comparison for sexes 
combined or for the gender subgroups.  
     Similar to the mean effect size calculation, calculation of random effects weighted odds ratios 
and 95% confidence intervals for each study were planned if sufficient comparisons existed. 
About half of the comparisons had less than 3 studies, indicating accurate calculation of the 
population variance would be difficult or not possible. A total of 6 comparisons included 3 or 
more studies and of these, only one (desvenlafaxine versus placebo for both sexes) had a 
calculated population variance different from 0; therefore, random effects weighted odds ratios 
were not calculated. As discussed previously, study characteristics were similar enough to 
support effect size calculations using fixed-effect model.
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Table 5. Mean Standardized Odds Ratios for Antidepressant by Sex 
Anti-
depressant  Sex Scale N 
Mean 
OR (a) SE Q 
Signifi-
cance 
of Q 
CI 
Low 
CI 
High 
Citalopram  Both CSFQ 1 0.275 0.197 - - -0.111 0.661 
Citalopram  Men CSFQ 1 0.393 0.312 - - -0.219 1.005 
Citalopram  Women CSFQ 1 0.164 0.259 - - -0.343 0.671 
Desvenla-
faxine Both ASEX 3 0.024 0.103 4.205 0.122 -0.179 0.226 
Desvenla-
faxine Men ASEX 1 0.149 0.430 - - -0.693 0.991 
Desvenla-
faxine Women ASEX 1 0.682 0.298 - - 0.098 1.265 
Duloxetine Both ASEX CSFQ 3 0.346 0.105 1.788 0.409 0.140 0.553 
Escitalopram  Both CSFQ 1 0.687 0.265 - - 0.168 1.206 
Paroxetine  Both ASEX 1 0.545 0.151 - - 0.250 0.841 
Vilazodone  Both ASEX CSFQ 3 0.105 0.100 0.167 0.920 -0.091 0.301 
Vilazodone  Men ASEX CSFQ 3 0.349 0.156 0.095 0.953 0.043 0.655 
Vilazodone  Women ASEX CSFQ 3 -0.088 0.132 0.189 0.910 -0.347 0.171 
Vortioxetine  Both ASEX 6 0.076 0.104 2.513 0.775 -0.128 0.279 
CSFQ = Changes in Sexual Functioning Questionnaire; ASEX = Arizona Sexual Experiences Scale; OR = odds 
ratio; SE = standard error; Q = the Q statistic; CI = confidence interval 
 
(a) Positive values indicate greater odds of developing sexual functioning compared to placebo. 
 
 Figures 8 and 9 show the odds ratio for developing sexual dysfunction by antidepressant 
compared to placebo. With both sexes combined, the odds of developing sexual dysfunction with 
paroxetine, escitalopram and duloxetine are significantly worse than placebo; however, the 
confidence intervals for duloxetine are narrow; therefore, more emphasis should be placed on the 
relative risk. 
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Figure 8. Odds Ratios of Developing Sexual Dysfunction, Antidepressant versus Placebo, Both 
Sexes Combined 
 
 
 
 Odds ratios by sex could not be calculated for all antidepressants included in the overall due 
to insufficient data presented in publications. Where data were available, the odds of developing 
sexual dysfunction versus placebo by sex were calculated and are presented in Figure 9. Gender 
differences are apparent with desvenlafaxine (worse in women) and vilazodone (worse in men). 
In most cases the results are consistent as expected from the standardized mean effect sizes with 
the exception of desvenlafaxine, which is worse in men based on total score effect sizes and 
contrasts with the odds ratios. As only one study contributed to the desvenlafaxine data, the 
conflicting results could be due to the smaller sample. 
Less than Placebo Greater than Placebo 
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Figure 9. Odds Ratios of Developing Sexual Dysfunction, Antidepressant versus Placebo, by Sex 
 
 
 
 
 
Less than Placebo Greater than Placebo 
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CHAPTER FIVE 
DISCUSSION  
The aim of this meta-analysis was to evaluate treatment-associated sexual dysfunction with 
second generation antidepressants utilizing studies that collected sexual functioning data via 
validated prospective questionnaires. It also included more recently approved antidepressants not 
found in previous meta-analyses, i.e., vilazodone and vortioxetine (‘atypical’ antidepressants). 
The results of this meta-analysis confirm that there are differences in the effects of 
antidepressants on sexual functioning, and that generally the SSRIs (e.g., citalopram, 
escitalopram, and paroxetine) have worse impact on sexual functioning than antidepressants of 
other classes, and that ‘atypical’ antidepressants (e.g., buproprion, vilazodone, and vortioxetine) 
have less impact on sexual functioning than either SSRIs or SNRIs (e.g., duloxetine, 
desvenlafaxine, and venlafaxine).  
 These results are not surprising given that SSRIs function by increasing serotonin in the 
brain, which is diminished in depressed individuals; however, the serotonergic system has an 
inhibitory effect on sexual desire, orgasm and ejaculation (Clayton et al., 2016). Antidepressants 
that target the norepinephrine, as well as serotonergic systems (SNRIs), or dopaminergic (e.g., 
buproprion) systems have a positive impact on sexual functioning, which may account for the 
fewer sexual side-effects. Furthermore, the specific serotonin receptors that are activated have 
differential effects on sexual functioning. Some 5-hydroxytriptamine (HT) receptors inhibit 
sexual activity, such as 5-HT3, the primary target of SSRIs, while others (5-HT1A) stimulate 
sexual functioning. Two of the recently approved antidepressants (vilazodone and vortioxetine) 
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have activity at the 5-HT1A receptor as well, which may mitigate some of the negative activity 
at the 5-HT3 receptor.  
 This analysis also highlighted some important gender effects on sexual functioning, which 
vary by antidepressant. Standardized mean change effect sizes indicated that overall paroxetine 
and escitalopram were associated with significantly greater sexual dysfunction compared to 
placebo, with the mean effect size for escitalopram being slightly worse than paroxetine. Gender 
differences were apparent with these two antidepressants; women had greater sexual dysfunction 
with escitalopram, and men had greater sexual dysfunction with paroxetine.  
 In general, the results of the mean odds ratio analysis confirmed the results of the 
standardized mean effect sizes. The odds of developing sexual dysfunction with escitalopram 
and paroxetine were significantly worse than placebo; however, each comparison was based on 
only one study, while the mean effect sizes were based on three comparisons for each. There was 
insufficient data to calculate odds ratios by gender for paroxetine and escitalopram. Interestingly, 
the odds of developing sexual dysfunction with duloxetine for both sexes combined was also 
significantly worse than placebo based on three comparisons; however, the mean effect size for 
duloxetine on any comparison did not differ significantly from placebo. In addition, the point 
estimate of the mean effect size for women on duloxetine was numerically worse compared to 
men. 
 As mentioned above, gender differences in the impact on sexual functioning were apparent 
for some of the antidepressants evaluated. In addition to paroxetine and escitalopram, significant 
differences were found in mean effect size and in the odds ratio between men taking vilazodone 
and placebo. However, in these comparisons, which included 4 comparisons for the mean effect 
size and 3 comparisons for the odds ratio, the effects for both sexes combined and for women did 
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not differ significantly from placebo. In addition, the odds of developing sexual dysfunction in 
women with desvenlafaxine were significantly worse than placebo, but that was not the case for 
men. The mean effect sizes for sexual functioning for desvenlafaxine versus placebo were not 
consistent with the odds ratios, that is, the trend was opposite although no effect size was 
significantly worse than placebo. In this case the odds ratios for sex were based on one 
comparison while the mean effect sizes were based on three comparisons; therefore, conclusions 
should be made with caution.  However, clear gender differences were seen with paroxetine, 
escitalopram and vilazodone, which highlights an important consideration that antidepressants 
can have differential effects on sexual functioning in men and women.  
 The results of this meta-analysis add to the body of information in the literature by in some 
cases confirming what has been reported, and it others adding with information on newer 
antidepressants. The level of sexual dysfunction with paroxetine is generally well known; 
however, some analyses have shown escitalopram to have less sexual dysfunction by comparison 
to other antidepressants than this analysis (Serretti & Chiesa, 2009), while other analyses 
confirm these two SSRIs are associated with worse sexual functioning compared to other 
antidepressants (Reichenpfader et al, 2014). This difference could be due to the small sample for 
the escitalopram comparison included in this analysis, or may reflect the varying methods of 
assessing sexual functioning in the studies included in other meta-analyses.  
 Few studies have evaluated the effects of antidepressants on sexual functioning utilizing 
validated questionnaires. Sexual dysfunction by adverse event reporting was not addressed in 
this analysis as it is well documented that spontaneous reporting of sexual dysfunction adverse 
events is very low and does not represent true levels of sexual dysfunction. Meta-analyses 
conducted to date (Serretti & Chiesa, 2009; and Reichenpfader et al, 2014) have generally cast a 
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wider net in order to include as much sexual functioning data as possible. While being inclusive 
has merit, it also suffers from increased heterogeneity across studies and brings into question the 
robustness of the results. For example, combining studies that do not utilize a validated 
questionnaire capable of assessing normal and abnormal sexual functioning with those that do, 
relies on greater manipulation of data based on assumptions. Analysis of studies that have 
utilized similar measures and procedures can allow for a more straighforward interpretation of 
results. Similarly comparisons to placebo are easier to interpret versus multiple comparisons 
between one antidepressant and another as in the Reichenpfader analysis. While this analysis had 
narrow selection criteria and was therefore less inclusive, the results have fewer confounding 
variables, e.g., not based on multiple measures that may not assess the same construct or based 
on adverse event reporting only which is known to be inaccurate.  
 The strict selection criteria resulted in a sample that had little heterogeneity across studies. 
Therefore, the use of a fixed effect model for reporting of mean effect sizes and odds ratios was 
justified, because the studies were consistent in design charateristics and the results of this 
analysis apply to MDD patients treated with antidepressants and are not intended to be 
generalized beyond this population. The limited number of studies that utilized validated 
questionnaires to assess sexual functioning in a randomized, placebo-controlled fashion, resulted 
in a smaller sample size which did not allow for analysis of effects by antidepressant dose or by 
sexual functioning subgroups. As research expands and more data is collected in this fashion, 
further analyses should be conducted that evaluates dose dependency of antidepressants on 
sexual functioning and on various dimensions of the sexual response cylce. Finally, conducting 
an analysis of this rigor (meeting the eligibility criteria) in a real-world setting would yield 
results that would more closely represent depressed patients receiving antidepressant treatment 
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versus clinical trial patients. To conduct a analysis of this kind would be challenging given that 
treatment providers do not typically administer validated sexual functioning questionnaires, and 
in cases where this is done, the data may not be accessible for analysis. Education of the 
importance of addressing sexual functioning issues in depressed patients, methods to accurately 
evaluate sexual functioning, and various treatment options will improve the assessment and 
treatment of sexual dysfunction, and hopefully lead to more systematic and accurate evaluation 
of antidepressant-associated sexual dysfunction. 
Limitations 
This meta-analysis has some limiations. There were relatively small number of comparisons for 
some antidpressants, as strict study eligibily criteria eliminated a number of studies that did not 
include placebo and/or did not include a validated questionnaire. All the eligible studies were 
funded by pharmaceutical companies and it is not known if individuals conducting studies 
meeting the same criteria would have resulted in different findings. Some commonly used 
antidepressants were not represented, such as sertraline, due to studies not meeting criteria. Older 
studies tended not to include the CSFQ-14 or ASEX as the use of validated questionnaires is 
more recent, and subsequently many of the older SSRIs are not represented. In additon, eligible 
studies included patients experiencing actute depression (experiencing a current major depressive 
episode). Fewer studies have evaluated the effects of antidepressants on sexual functioning in 
patients whose depression symptoms are well-treated. Since sexual dysfunction is associated 
with depression even in the absense of antidepressant treatment, depression symptoms are a 
confounding effect. Therefore, selecting studies that are similar in inclusion criteria for the 
severity of depression helps to reduce the effects of this confounder. Because many of the studies 
included more than one active treatment (antidepressant) compared to placebo, multiple 
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comparisons to placebo were made in calculating effect sizes within study which intruduces 
dependency of effect sizes.   
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Step 1: Study Identifiers, Study Design, Patient Selection, Sexual functioning assessment. 
STUDY IDENTIFIERS 
Each study will have its own unique Study identifier (e.g., StudyID 12). If there is more than one 
study within the same source (e.g., journal article references multiple studies), then the source 
will have multiple study ID numbers, and each study will be coded on separate coding sheets. If 
there is more than one reference for a particular research study, then the coding should be done 
from the most complete source of data (e.g., publication). If data fields are incomplete using only 
one source of data, another data source can be utilized if the criteria are met. Each data source 
will have its own unique identifier (e.g., 12.1; 12.2, etc.), but may be coded on the same set of 
coding sheets. The relevant fields should be coded from the most appropriate source with the 
study ID noted in the margin if one set of coding sheets is used. 
If data is missing and there is no coded option for a required field enter NA for not applicable or 
UNK for unknown. If entire section is not applicable, leave blank or line through. 
[StudyID]_________ If multiple sources, list all here if using one coding sheet. Also, indicate in 
margins StudyID for source of data. 
[Coder] Coder’s initials:________ 
[CodDT]_________ (Date coding began) 
[QCDT]__________ (only use for recoding or QC review of coding is done) 
[CMNTS]: This field used to comment on relevant information that is not captured in other 
fields. 
[PubYR] Publication: ________ (Year of publication, FDA review or posting of results online) 
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[Region] Region study was conducted: 
A. United States 
B. Europe 
C. Asia 
D. South Africa 
E. Global 
F. Other_________________ [Region1] 
G. UNK 
[PubTyp] Type of publication: 
A. Journal article 
B. Clinicaltrials.gov 
C. Summary Basis of Approval (SBA) 
STUDY DESIGN 
[Source] Source of data:  
A. Single study 
B. Pooled studies. 
[Rand] Method of study randomization 
A. Centralized/IVR/IRT 
B. Site 
C. UNK 
[Bias] Risk of bias in randomization assignments: 
A. Low (potential for bias) 
B. Unclear 
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C. High (bias based on methodology) 
[Blind] Blinding method: 
A. Double-blind 
B. Single-blind 
C. None (note this is exclusionary) 
[PBO] Was study placebo-controlled?  
A. Yes 
B. No 
[Dur] Treatment duration in weeks _______ (If several, select the acute phase, e.g., 6-12 weeks) 
[Visit] Number of study visits during treatment? ___________ (including Baseline) 
[Design] Study design: 
A. Parallel 
B. Active-reference 
C. Comparator/head-to-head 
[Arms] Number of study arms including placebo______ 
[STDrug] Name of study drug: ______________________________ 
[STReg] Regimen (eg QD): ____________________________ 
[STflex] Fixed or flexible dosing? (do not include titration) 
A. Fixed 
B. Flexible  
C. Dose increase allowed 
[STDose1] Dose of study drug: _____________________________mg (if flexible put low dose) 
[STDose2] Second dose of study drug: ______________________mg (if flexible put high dose) 
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[Titrate1] Was study drug 1 titrated? 
A. Yes 
B. No 
C. NA 
[ActDrug] Name of reference or comparator drug, if applicable: _____________________ 
[ActReg] Regimen (eg QD): ____________________________ 
[Actflex] Fixed or flexible dosing? (do not include titration) 
A. Fixed  
B. Flexible 
C. Dose increase allowed 
[ActDose1] Dose of reference/comparator drug:______________mg (if flexible put low dose) 
[ActDose2] Second dose of reference/comparator drug:_________mg (if flexible put high dose) 
[Titrate2] Was the reference or comparator drug titrated, if applicable? 
A. Yes 
B. No 
C. NA 
[Primary] What was the primary objective of the study? 
A. Sexual dysfunction 
B. MDD 
C. UNK 
D. Both 
[Outcome] Overall result on the efficacy endpoint: 
A. Significant differences found 
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B. No significant differences found 
C. Mixed 
SUBJECT SELECTION CRITERIA 
[DX] Patient diagnosis for entry to study: 
A. MDD 
B. Recurrent MDD 
C. Depression not specified per diagnostic criteria 
[Status] Depressive episode status: 
A. Acute 
B. Stable 
C. Remitted 
[Episode] Criteria for duration of current depressive episode in weeks._______ 
[AgeGrp] Age group enrolled ______________ E.g., 18+, 18-65, 18-45 
[MDREnt] Entry criteria for MADRS, if applicable: ______  
[HMDEnt] Entry criteria for HAM-D17, if applicable: ______ 
[CGIEnt] Entry criteria for CGI-S, if applicable: ______ 
[AxisIEx] Excluded any other axis I other than MDD? 
A. Yes 
B. No 
[NonRes] Excluded non-responders to treatment? 
A. Yes 
B. No 
  
    69 
 
[MedCon] Excluded significant medical conditions? 
A. Yes 
B. No 
[SexDys] Excluded Sexual dysfunction disorders? 
A. Yes 
B. No 
[Sexfxn] Sexual functioning enrollment status 
A. All 
B. Normal  
C. Abnormal 
MDD EFFICACY ASSESSMENT 
[Effic] Type of efficacy endpoint, if measured: 
A. MADRS 
B. HAM-D17 
C. Other _____________________ [EffScale] 
[Effect] Type of treatment effect of therapy reported, if assessed. 
A. Mean change from baseline total score 
B. Mean change from baseline total score, difference to placebo/active 
SEXUAL FUNCTIONING ASSESSMENT 
[Scale] Scale used to assess sexual functioning: 
A. ASEX 
B. CSFQ 
[Specify] Other: ___________________ 
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[Version] Version of scale used to assess sexual functioning (e.g., short form, full scale, or 
version number)___________ 
[Subs] Subscales reported? 
A. Yes 
B. No 
[Single] Single items reported? 
A. Yes 
B. No 
[Shift] Shift assessment reported (eg, shift from normal to abnormal functioning)? 
A. Yes 
B. No 
[SDScore] Primary score data reported? 
A. Mean change from Baseline total score 
B. Mean change from Baseline total score difference to placebo 
C. Mean change from Baseline total score difference to active control/reference 
D. Shift from normal to abnormal sexual functioning 
PATIENT DEMOGRAPHICS TOTAL POPULATION 
[TotalN] Total patients randomized _______________ Includes all treatment groups 
[FAS] Full analysis set (total patients included in primary analysis) ____________ N for the 
primary results often listed in table, note this is not the N for safety set which is usually used for 
Baseline characteristics. Demographic data below is usually derived from safety set. 
[CmpltN] Number of patients completing study ______________ 
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[LTFU] Number of patients lost to follow-up ______________ 
[WDAE] Number of patients who withdrew due to adverse event _________ 
[Female] Percent Female whole study _____________ 
[Race…] Percent each 
A. Percent Caucasian______[RaceA] 
B. Percent Black_______[RaceB] 
C. Percent Asian_______[RaceC] 
D. Percent Hispanic_______[RaceD] 
E. Other______[RaceE] 
[AgeMn] Mean age. ____________ 
[MDEMn] Mean duration of MDE in weeks. _____________ 
[EpisMn] Mean number of prior episodes. ___________ 
[MDRMn] Mean baseline MADRS total score. _________ 
[HMDMn] Mean baseline HAM-D17 total score. ___________ 
[CGIMn] Mean CGI-S score. __________ 
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STUDY OUTCOMES: BASELINE CHARACTERISTICS 
Use multiple pages to complete this section. Data coded in database as A, B, C, or D then 
remaining field name. Pages should be labeled 6A-9A, 6B-9B on coding sheets, etc, based 
on response to [Group] below. 
[StudyID]: __________ [Coder] Coder’s initials:________ 
[Group] Study group being coded: 
A. Placebo 
B. Study drug dose 1 (use if only 1 dose or lower dose) 
C. Study drug dose 2 (higher dose if more than 1 dose) 
D. Active reference/comparator 
[…GrpN] Number of patients included in group. __________ (# included for BL sexual 
functioning scores, N usually provided for results) 
[…GrpFem] Percent Female in group. _____________ 
Percent each 
A. Percent Caucasian_______ […GrpRacA] 
B. Percent Black________ […GrpRacB] 
C. Percent Asian_______ […GrpRacC] 
D. Percent Hispanic _______ […GrpRacD] 
E. Other_______ […GrpRacE] 
[…GrpAge] Mean group age. ____________ 
[…GrpMDE] Mean duration of MDE in weeks. _____________ 
[…GrpEpis] Mean number of prior episodes. ___________ 
[…MDRBL] Mean baseline MADRS total score. _________ 
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[…HMDBL] Mean baseline HAM-D17 total score. ___________ 
[…CGIBL] Mean baseline CGI-S score. __________ 
Baseline sexual functioning status 
[…BLNorm] Baseline percent normal sexual functioning (both sexes)__________ 
[…BLNormM] Baseline percent normal sexual functioning male. _________ 
[…BLNormF] Baseline percent normal sexual functioning female. __________ 
[…BLAbn] Baseline percent abnormal sexual functioning (both sexes)__________ 
[…BLAbnM] Baseline percent abnormal sexual functioning male. _________ 
[…BLAbnF] Baseline percent abnormal sexual functioning female. _________ 
[…BLSDAE] Baseline sexual dysfunction adverse events (percent) __________ 
Baseline sexual function scale scores (Score/Standard Deviation/Error) 
Enter either SD or SE if provided. Indicate UNK if neither is provided. If SD is provided, leave 
SE blank. 
[..SFBL] BL Sexual fxn total/mean score (both sexes)_____[..SDBL]___[..SEBL]______ 
[…SFBLM] BL Sexual fxn total/mean score male _____[..SDBLM]____[..SEBLM]____ 
[…SFBLF] BL Sexual fxn total/mean score female ____[..SDBLF]____[..SEBLF]_____ 
Baseline Subscales or sub-items (Score/Standard Deviation/Error) Cross out if NA 
Enter either SD or SE if provided. Indicate UNK if neither is provided. If SD is provided, leave 
SE blank. Eg for subscale names enter, “Pleasure” or “Desire/Freq,” or “Desire/Int” etc. Order 
used should be same order as per the instrument. Enter the N for each subgroup, note that the Ns 
may all be the same across each subscale group. 
[…SFsub1] Subscale/item name #1_____________________ Grp N: ______[..SFsub1N] 
[…Sub1] Subscale/item BL score (both sexes)_______[..SDBL1]______[..SEBL1]_____ 
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[…Sub1M] Subscale/item BL score male _______[..SDBL1M]______[..SEBL1M]_____ 
[…Sub1F] Subscale/item BL score female______[..SDBL1F]_______[..SEBL1F]______ 
[…SFsub2] Subscale/item name #2 ______________________Grp N: _______[..SFsub2N] 
[…Sub2] Subscale/item BL score (both sexes)______[..SDBL2]______[..SEBL2]______ 
[…Sub2M] Subscale/item BL score male______[..SDBL2M]______[..SEBL2M]______ 
[…Sub2F] Subscale/item BL score female_______[..SDBL2F]______[..SEBL2F]______ 
[…SFsub3] Subscale/item name #3 _____________________Grp N: ________[..SFsub3N] 
[…Sub3] Subscale/item BL score (both sexes)______[..SDBL3]______[..SEBL3]______ 
[…Sub3M] Subscale/item BL score male ______[..SDBL3M]______[..SEBL3M]______ 
[…Sub3F] Subscale/item BL score female______[..SDBL3F]______[..SEBL3F]_______ 
[…SFsub4] Subscale/item name #4 ____________________ Grp N: _________[..SFsub4N] 
[…Sub4] Subscale/item BL score (both sexes)_______[..SDBL4]______[..SEBL4]_____ 
[…Sub4M] Subscale/item BL score male ______[..SDBL4M]______[..SEBL4M]______ 
[…Sub4F] Subscale/item BL score female_______[..SDBL4F]______[..SEBL4F]______ 
[…SFsub5] Subscale/item name #5 _____________________ Grp N:________[…SFsubN5] 
[…Sub5] Subscale/item BL score (both sexes)______[..SDBL5]______[..SEBL5]______ 
[…Sub5M] Subscale/item BL score male ______[..SDBL5M]______[..SEBL5M]______ 
[…Sub5F] Subscale/item BL score female______[..SDBL5F]______[..SEBL5F]_______ 
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STUDY OUTCOMES: ENDPOINT 
Enter endpoint as mean total score if provided. If endpoint score is listed as mean change 
from Baseline, or difference to Placebo or active ONLY, the total score should to be 
calculated and entered here. Indicate if calculated. If unable to calculate, enter as provided 
with note in margin. 
[…MDREP] Mean endpoint MADRS total score. _________ 
[…HMDEP] Mean endpoint HAM-D17 total score. ___________ 
[…CGIEP] Mean endpoint CGI-S score. __________ 
[…Rem] Percent remission __________ 
[…Resp] Percent responders __________ 
Endpoint sexual functioning status including TESD/shift assessment (line through if not 
reported, leave blank). Note that shift analysis includes only subjects who initiate treatment 
with Normal sexual functioning and shift to Abnormal. 
[…EPNorm] Endpoint percent normal sexual functioning (both sexes)._________  
[…EPNormM] Endpoint percent normal sexual functioning male. _______ 
[…EPNormF] Endpoint percent normal sexual functioning female. _______ 
[…EPAbn] Endpoint percent abnormal sexual functioning (both sexes).________ 
[…EPAbnM] Endpoint percent abnormal sexual functioning male. _________ 
[…EPAbnF] Endpoint percent abnormal sexual functioning female. _________ 
[…Shift] Percent shift to abnormal sexual functioning (both sexes).___________ 
[…ShiftM] Percent shift to abnormal sexual functioning Male. _________ 
[…ShiftF] Percent shift to abnormal sexual functioning Female. _________ 
[…EPSDAE] Endpoint sexual dysfunction adverse events (percent). __________ 
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Endpoint sexual function scale scores 
[…SFEP] End sexual function total score (both sexes) ________[..SD]_______[..SE]_______ 
[…SDEPM] End sexual function total score male_______[..SDM]______[..SEM]_____ 
[…SDEPF] End sexual function total score female ______[..SDF]______[..SEF]______ 
 […SFChg] Sexual fxn change from BL (both sexes) _______[..SDChg]______[..SEChg]_____ 
[…SFChgM] Sexual fxn change from BL male_____[..SDChgM]_____[..SEChgM]____ 
[…SFChgF] Sexual fxn change from BL female _____[..SDChgF]_____[..SEChgF]____ 
Endpoint Subscales or sub-items (Score/Std Deviation/Error) Cross out if NA 
Enter either SD or SE if provided. Indicate UNK if neither is provided. If SD is provided, leave 
SE blank. Transfer subscale/item name from Baseline section. Use same order. 
[…SFsub1] Subscale/item name #1_______________________(same as BL) 
[…Sub1EP] Subscale/item end score (both sexes)_________[..SD1]________[..SE1]_________ 
[…Sub1EPM] Subscale/item end score male _______[..SD1M]_______[..SE1M]______ 
[…Sub1EPF] Subscale/item end score female_______[..SD1F]_______[..SE1F]_______ 
[…Sub1Chg] Subscale change score (both sexes)______ [..SDChg1]______[..SEChg1]_______ 
[…Sub1ChgM] Subscale Change score male _____[..SDChg1M]_____[..SEChg1M]___ 
[…Sub1ChgF] Subscale Change score female_____[..SDChg1F]_____[..SEChg1F]____ 
[…SFsub2] Subscale/item name #2 _______________________(same as BL) 
[…Sub2EP] Subscale/item end score (both sexes) ________[..SD2]_______[..SE2]______ 
[…Sub2EPM] Subscale/item end score male _____[..SD2M]______[..SE2M]_____ 
[…Sub2EPF] Subscale/item end score female_____[..SD2F]_______[..SE2F]______ 
[…Sub2Chg] Subscale change score (both sexes) _______[..SDChg2]______[..SEChg2]____ 
[…Sub2ChgM] Subscale change score male _____[..SDChg2M]_____[..SEChg2M]__ 
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[…Sub2ChgF] Subscale change score female_____[..SDChg2F]_____[..SEChg2F]____ 
[…SFsub3] Subscale/item name #3 _______________________(same as BL) 
[…SubEP3] Subscale/item end score (both sexes) ________[..SD3]_______[..SE3]________ 
[…Sub3EPM] Subscale/item end score male ______[..SD3M]_______[..SE3M]_____ 
[…Sub3EPF] Subscale/item end score female_______[..SD3F]_______[..SE3F]_______ 
[…Sub3Chg] Subscale change score (both sexes) _______[..SDChg3]______[..SEChg3]______ 
[…Sub3ChgM] Subscale change score male ______[SDChg3M]______[SEChg3M]____ 
[…Sub3ChgF] Subscale change score female______[SDChg3F]______[SEChg3F]_____ 
[…SFsub4] Subscale/item name #4 _______________________(same as BL) 
[…SubEP4] Subscale/item end score (both sexes) _________[..SD4]_________[..SE4]________ 
[…Sub4EPM] Subscale/item end score male _______[..SD4M]_______[..SE4M]______ 
[…Sub4EPF] Subscale/item end score female_______[..SD4F]_______[..SE4F]______ 
[…Sub4Chg] Subscale change score (both sexes)________[..SDChg4]______[..SEChg4]______ 
[…Sub4ChgM] Subscale change score male______[..SDChg4M]____[..SEChg4M]____ 
[…Sub4ChgF] Subscale change score female ____[..SDChg4F]_____[..SEChg4F]_____ 
[…SFsub5] Sub-item/ sub scale name _______________________(same as BL) 
[…SubEP5] Sub-item/ subscale endpoint score__________SD5_____ 
[…Sub5EPM] Sub-item/ subscale endpoint score male _________SD5M_____ 
[…Sub5EPF] Sub-item/ subscale endpoint score female__________SD5F_____ 
[…Sub5Chg] Sub-item/subscale endpoint change from BL__________SE5_____ 
[…Sub5ChgM] Sub-item/ subscale endpoint change from BL male ___SE5M___ 
[…Sub5ChgF] Sub-item/ subscale endpoint change from BL female___SE5F___ 
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Any data that are not provided, but can be calculated from other data present should be done and 
entered. Show calculation on coding sheet, use back or margin. Indicate next to field that data 
was calculated, e.g.,“Calc”
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SEXUAL DYSFUNCTION ASSESSMENT TOOLS 
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APPENDIX C 
EFFECT SIZES BY STUDY 
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Effect sizes by study. 
Study  
Identifier (a) 
Antidepressant 
arms 
Mean 
ES SE Q 
Signifi-
cance of 
Q 
CI Low CI High 
1.Clayton et 
al., 2006 
Buproprion  
Escitalopram  
Placebo 
-0.075 0.056 3.171 0.075 -0.185 0.035 
2.Clayton et 
al., 2006 
Buproprion  
Escitalopram  
Placebo 
-0.064 0.056 5.212 0.022* -0.174 0.046 
3.Clayton et 
al., 2007 
Duloxetine 
Escitalopram 
Placebo 
-0.157 0.056 0.710 0.701 -0.266 -0.047 
4.Clayton, 
Reddy, et al., 
2013; 
Dunlop, et 
al., 2011 
Desvenlafaxine 
Placebo 0.129 0.073 - - -0.014 0.272 
6.Clayton, 
Kennedy, et 
al., 2013; 
Rickels et 
al., 2009 
Vilazodone 
Placebo 0.027 0.064 - - -0.099 0.152 
7.Clayton, 
Kennedy et 
al., 2013; 
Khan et al., 
2011 
Vilazodone 
Placebo -0.055 0.063 - - -0.177 0.068 
8.Clayton, 
Tourian, et 
al, 2015  
Desvenlafaxine 
Desvenlafaxine 
Placebo 
-0.033 0.054 0.104 0.747 -0.138 0.073 
9.Clayton, 
Gommoll, et 
al., 2015; 
Mathews et 
al., 2015 
Vilazodone 
Vilazodone 
Citalopram 
Placebo 
0.040 0.036 1.194 0.552 -0.111 0.031 
11.Hewett et 
al., 2010 
Buproprion 
Venlafaxine 
Placebo 
0.031 0.045 0.046 0.830 -0.058 0.120 
12.Boulenge
r et al., 2014 
Clinicaltrials
.gov 
Vortioxetine 
Vortioxetine 
Duloxetine 
Placebo 
0.130 0.042 4.262 0.119 0.047 0.213 
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Study  
Identifier (a) 
Antidepressant 
arms 
Mean 
ES SE Q 
Signifi-
cance of 
Q 
CI Low CI High 
NCT011409
06 
13.Mahables
hwarkar, 
Jacobsen, 
Chen et al., 
2015 
Vortioxetine 
Vortioxetine 
Duloxetine 
Placebo 
0.038 0.047 0.485 0.785 -0.055 0.131 
14.Jacobsen 
et al., 2015 
Vortioxetine 
Vortioxetine 
Placebo 
0.089 0.056 0.034 0.853 -0.021 0.199 
15.Mahables
hwarkar, 
Jacobsen, 
Serenko et 
al., 2015 
Vortioxetine 
Vortioxetine 
Placebo 
-0.031 0.056 1.74 0.187 -0.140 0.078 
16. 
F1J-MC-
HMATa 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
-0.183 0.072 2.108 0.349 -0.324 -0.042 
17. 
F1J-MC-
HMATb 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
-0.080 0.074 0.003 0.998 -0.225 0.066 
18.  
F1J-MC-
HMAYa 
Duloxetine 
Duloxetine 
Paroxetine 
Placebo 
-0.146 0.072 1.439 0.487 -0.288 -0.005 
ES = effect size; SE = standard error; Q = the Q statistic; CI = confidence interval 
 
(a) Pooled studies 5 and 10 are not included since mean effect sizes were calculated from the individual studies. 
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